Statis tical Analysis Plan  
Final  
Effective Date: 11-Dec-2018/Version 3.0 
Sponsor: Estetra  
Protocol no: MIT -Es0001 -C302  
PRS 005 T 17 E  Page 1 of 45 
Strictly Confidential. Â© 2004 -2014, PRA  Health Sciences. All rights reserved.  
 
Statistical Analysis Plan  
 
Sponsor:  Estetra  
Protocol No:  MIT-Es0001 -C302 
Version No./Date  Final 1.1/ 10-July-[ADDRESS_1129744] ration N o. [STUDY_ID_REMOVED]  
CRF Version 
No./Date  3.0/18-July-[ADDRESS_1129745] Id:  MHUEC302 -ESC302  
SAP Version  
No./Date:  3.0/11 Dec ember  2018  
Approvals  
Sponsor  
Sponsor Name:  [CONTACT_815917]/ Title:  Sophie Ledant, Clinical Pro ject Leader  
Signature /Date:   
 
Sponsor Name:  [CONTACT_815917]/ Title:  Marie Mawet, Medical Advisor  
Signature /Date:   
 
PRA  
Project Manager/Title:  LaÃ«titia Poher, Project Director  
Signature /Date:   
 
Biostatistician / Title:  Jess Sadler , Senior Principal Biostatistician  
Signature /Date:   
 
  
Statis tical Analysis Plan  
Final  
Effective Date: 11-Dec-2018/Version 3.0 
Sponsor: Estetra  
Protocol no: MIT -Es0001 -C302  
PRS 005 T 17 E  Page 2 of 45 
Strictly Confidential. Â© [ADDRESS_1129746] -Treatment Pregnancies  ................................ ................................ ................................ ........................  14 
5.9.4 Method and User Failure Pregnancies  ................................ ................................ ................................ ..... 14 
5.10 Bleeding Patterns  ................................ ................................ ................................ ................................ ...................  15 
5.10.1 Definitions of Bleeding and Spotting ................................ ................................ ................................ ...... 15 
5.10.2 Cycle analysis  ................................ ................................ ................................ ................................ ...................  15 
5.10.3 Reference Periods (RPs)  ................................ ................................ ................................ ..............................  17 
5.10.4 Bleeding Endpoints for the Cycle Analysis  ................................ ................................ ..........................  17 
5.10.5 Bleeding Endpoints for Analyses by [CONTACT_143005]  ................................ ................................ ................................  19 
5.11 Treatment -Emergent Adverse Event (TEAE)  ................................ ................................ .............................  19 
5.12 Quality of Life Enjoyment and Satisfaction Questionnaire Short Form (Q -LES-Q-SF) ...............  19 
5.13 Menstrual Distress Questionnaire  ................................ ................................ ................................ ...................  20 
5.14 Return to Fertility  ................................ ................................ ................................ ................................ ...................  20 
5.15 Methods for Handling Missing Data  ................................ ................................ ................................ ................  20 
5.15.1 Missing Data Related to the Pearl Index and Pi[INVESTIGATOR_815801]  ................................ ................................  20 
5.15.2 Missing Bleeding Data  ................................ ................................ ................................ ................................ .. 21 
Statis tical Analysis Plan  
Final  
Effective Date: 11-Dec-2018/Version 3.0 
Sponsor: Estetra  
Protocol no: MIT -Es0001 -C302  
PRS 005 T 17 E  Page 3 of 45 
Strictly Confidential. Â© 2004 -2014, PRA  Health Sciences. All rights reserved.  
5.15.3 Missing or Partial Dates for Medications  ................................ ................................ .............................  21 
5.15.4 Missing or Partial Dates for AEs  ................................ ................................ ................................ ...............  22 
5.15.5  Missing or Partial Treatment Start and Stop Dates  ................................ ................................ .........  22 
6.0 Analysis Sets  ................................ ................................ ................................ ................................ ................................ ..... 23 
6.1 Screened Population  ................................ ................................ ................................ ................................ ................  23 
6.2 Enrolled Population  ................................ ................................ ................................ ................................ .................  23 
6.3 Safety Population  ................................ ................................ ................................ ................................ ......................  23 
6.4 Intention -to-Treat (ITT) Population  ................................ ................................ ................................ .................  23 
6.5 Per -Protocol (PP) Population  ................................ ................................ ................................ ...............................  23 
6.6 Pharmacokinetics (PK) Population  ................................ ................................ ................................ ....................  [ADDRESS_1129747] -Study Treatment and Concomitant Medications  ................................ ..........................  26 
9.4 Demographic and Baseline Characteristics  ................................ ................................ ................................ .... 26 
9.5 Efficacy Analyses  ................................ ................................ ................................ ................................ .......................  27 
9.5.1 Primary Variable  ................................ ................................ ................................ ................................ ...............  27 
9.5.2 Secondary Variables  ................................ ................................ ................................ ................................ ........  28 
9.5.3 Bleeding a nd Spotting  ................................ ................................ ................................ ................................ ..... 30 
9.6 Safety Analyses  ................................ ................................ ................................ ................................ ...........................  32 
9.6.1 Adverse Events  ................................ ................................ ................................ ................................ ..................  32 
9.6.2  Deaths and Serious Adverse Events  ................................ ................................ ................................ ..........  32 
9.6.3 Laboratory Data ................................ ................................ ................................ ................................ .................  33 
9.6.4 Vital Signs  ................................ ................................ ................................ ................................ .............................  34 
9.6.5 Physical and Gynecological Examinations  ................................ ................................ ..............................  34 
9.7 Other Secondary Endpoints (Excluding PK)  ................................ ................................ ................................ .. 34 
9.7.1 Quality of  Life ................................ ................................ ................................ ................................ .....................  34 
9.7.2 Follow -Up Evaluations ................................ ................................ ................................ ................................ .... 34 
9.8 Population Pharmacokinetics Analysis  ................................ ................................ ................................ ............  35 
9.8.1 Data Included in Analysis  ................................ ................................ ................................ ..............................  35 
9.8.2 Objectives  ................................ ................................ ................................ ................................ .............................  35 
9.8.3 Assumptions  ................................ ................................ ................................ ................................ .......................  35 
9.8.4 Prespecified Hypotheses  ................................ ................................ ................................ ................................  35 
9.8.5 Study MIT -Es0001 -C302  ................................ ................................ ................................ ................................  36 
9.8.6 Study Es0001 -C101 ................................ ................................ ................................ ................................ ..........  36 
9.8.7 Study MIT -Es0001 -C103  ................................ ................................ ................................ ................................  37 
9.8.8 Data management  ................................ ................................ ................................ ................................ .............  37 
9.8.9 Data Deletion  ................................ ................................ ................................ ................................ ......................  38 
9.8.10 PopPK Model Development  ................................ ................................ ................................ .......................  38 
9.8.11 PopPK Model Evaluation  ................................ ................................ ................................ .............................  39 
Statis tical Analysis Plan  
Final  
Effective Date: 11-Dec-2018/Version 3.0 
Sponsor: Estetra  
Protocol no: MIT -Es0001 -C302  
PRS 005 T 17 E  Page 4 of 45 
Strictly Confidential. Â© 2004 -2014, PRA  Health Sciences. All rights reserved.  
9.8.12 Reporting  ................................ ................................ ................................ ................................ ...........................  39 
9.8.13 Source Files  ................................ ................................ ................................ ................................ .......................  40 
10.0 Validation  ................................ ................................ ................................ ................................ ................................ ........  41 
11.0 R eferences  ................................ ................................ ................................ ................................ ................................ ...... 41 
12.0 Amendment to the Statistical Analysis Plan  ................................ ................................ ................................ ..... 41 
12.1 Amendment 1 from SAP dated 12 December 2016 ................................ ................................ ..................  41 
12.2 Amendment 2 from SAP dated 13 November 2018  ................................ ................................ .................  43 
Appendix 1 Glossary of Abbreviations  ................................ ................................ ................................ .........................  44 
 
 
 
 
 
  
Statis tical Analysis Plan  
Final  
Effective Date: 11-Dec-2018/Version 3.0 
Sponsor: Estetra  
Protocol no: MIT -Es0001 -C302  
PRS 005 T 17 E  Page 5 of 45 
Strictly Confidential. Â© 2004 -2014, PRA  Health Sciences. All rights reserved.  
1.0 Introduction  
This statistical analysis plan (SAP) describes the statistical methods to be used during the reporting and 
analyses of data collected under Estetra  Protocol MIT-Es0001 -C302.  
This SAP should be read in conjunction with the study protocol and case report fo rm (CRF). This version 
of the plan has been developed using the protocol  amendment 1.[ADDRESS_1129748] ive 
The primary objective of this study is to evaluate the contraceptive efficacy of 15 mg Estetrol (E4)/3 mg 
Drospi[INVESTIGATOR_187306] (DRSP) using the Pearl Index in subjects aged 16 to 35 years, inclusive, at the time of 
screening.  
2.2 Secondary Efficacy Objectives  
The secondary objectives of this study are:  
1. To evaluate the contraceptive efficacy of 15 mg E4/3 mg DRSP using the method failure Pearl 
Index and life -table analysis in subjects aged 16 to 35 years, inclusive, at the time of screening  
2. To evaluate the contracep tive efficacy of 15 mg E4/3 mg DRSP using the Pearl Index, the method 
failure Pearl Index and life -table analysis in the overall study population  
2.3 Other Secondary Objectives  
1. To evaluate cycle control and bleeding pattern associated with 15 mg E4/3 mg DRSP  
2. To evaluate general safety of 15 mg E4/[ADDRESS_1129749] of 15 mg E4/[ADDRESS_1129750] of various individual characteristics/covariates ( e.g., body weight, race, a nd 
smoking) on the pharmacokinetics (PK) of 15  mg E4/3 mg DRSP (Population PK Substudy)  
3.[ADDRESS_1129751] of the 
subjects, which is approximately 13 -15 months. Those subjects who discontinue and desire pregnancy will 
be followed for a maximum of one year after study discontinuation for return of spontaneous menstruation 
and until pregnancy or initiation of a contraceptive method (whichever occurs first).  
Approximately 2000 healthy female subjects at-risk for pregnancy, between 16 and 50 years old (inclusive, 
at the time of screening), and requesting contraception will be enrolled in the study. In total 1800 subjects 
will be 16 to 35 years old (inclusive). Recruitment may be stopped when [ADDRESS_1129752] been enrolled 
if the required number of subjects for the primary analysis (1800 subjects in the age group up to 35 years) 
has been reached. Recruitment of women aged [ADDRESS_1129753] been enrolled.  
Eligible subjects will be treated with 15 mg E4/[ADDRESS_1129754] be taken once daily at approximately the  same time of the day in a 24/4 -day regimen, 
i.e. 24 active tablets followed by 4 placebo tablets (4 -day hormone free interval).  
Statis tical Analysis Plan  
Final  
Effective Date: 11-Dec-2018/Version 3.0 
Sponsor: Estetra  
Protocol no: MIT -Es0001 -C302  
PRS 005 T 17 E  Page 6 of 45 
Strictly Confidential. Â© 2004 -2014, PRA  Health Sciences. All rights reserved.  
The primary study objective is to evaluate the contraceptive efficacy of the new Combined Oral 
Contraceptive (COC), using the P earl Index calculation (which reflects the pregnancy rate associated with 
a contraceptive method) among the subjects aged 16 to 35 years inclusive.  
The contraceptive efficacy will also be evaluated using the method failure Pearl Index (which reflects the 
pregnancy rate due to method failure only) and life -table analysis in the subjects aged [ADDRESS_1129755] examinations and by [CONTACT_815875], frequency, type and 
intensity of adverse events (AEs) and serious adverse events (SAEs).  
Participating subjects will be asked to record daily in a subject diary their blee ding/spotting epi[INVESTIGATOR_1841]. This 
will allow evaluating the bleeding pattern and the cycle control associated with the investigational product.  
Treatment compliance will be assessed using data from the subject diary across the entire study and by 
[CONTACT_815876], in the case of a pregnancy, detailed information from a pregnancy narrative completed by [CONTACT_815877].  The subject diary will also be used to determine whether or not a cycle is an at-
risk cycle for the Pearl Index calculation. In the prima ry analysis of the Pearl Index, at-risk cycles will be 
defined as cycles in which the following criteria are met:  
1. No other methods of birth control (including condoms  and emergency contraception ) are used by 
[CONTACT_815878]  
2. The subject confirmed that sexual intercourse occurred during the cycle in the subject diary  
Note that if conception occurs in a cycle, then that cycle will be included as an at-risk cycle in the 
denominator even if any other contraceptive method was used d uring that cycle or the subject did not 
confirm that sexual intercourse occurred. Cycles after the cycle of conception will not be included as at-risk 
cycles and will be excluded from the denominator.  
Physical, psychological and social functioning and well -being associated with the investigational product 
will be assessed with well -established questionnaires. A study schedule of events is provided in Appendix 
1 of the Protocol. Population PK will be assessed using plasma E4 and DRSP concentration data from a 
subset of approximately 500 subjects to evaluate the relationship between E4 and DRSP PK parameters 
and various characteristics (e.g., body weight, race, and smoking). Blood samples for PK analysis will be 
obtained at Visits [ADDRESS_1129756] a sufficient number of cycles such that the difference between 
the Pearl Index and the  upper limit of the two -sided 95% confidence interval (CI) for the Pearl Index d oes 
not exceed 1. Assuming that the true Pearl Index is 1.[ADDRESS_1129757] 12,337 at-risk cycles are required for a power of 90% in the 16 to 35 year old population  
(Gerlinger  et al., 2003 ).  
Assuming 80% of the study cycles are at-risk cycle and a dropout rate of approximately 45% (assuming 
that we have an average of 4 cycles for subjects that discontinue) are assumed, approximately 1800 16 -
to-35 year old subjects need to be enrolled. Additionally, it is planned to enroll a maximum of 200 subjects 
36-50 years. Therefore, in total, approximately 2000 subjects will be enrolled in the study. Additionally, a 
subset of approximately 500 subjects will be enrolled in the PK Substudy.   
4.0 Study Variables and Covariates  
4.1 Primary Variable  
The primary efficacy variable will be the number of on -treatment pregnancies assessed by [CONTACT_815879] 16 to 35 years, inclusive, at the time of screening with at-risk cycles (c ycles in 
Statis tical Analysis Plan  
Final  
Effective Date: 11-Dec-2018/Version 3.0 
Sponsor: Estetra  
Protocol no: MIT -Es0001 -C302  
PRS 005 T 17 E  Page 7 of 45 
Strictly Confidential. Â© 2004 -2014, PRA  Health Sciences. All rights reserved.  
which no other methods of birth control (including condoms and emergency contraception)  are used and 
during which the subjects confirmed that sexual intercourse has occurred).  
4.2 Secondary Variables  
4.2.1  Efficacy  
The secondary efficacy variables are:  
1. The number of on -treatment pregnancies as assessed by [CONTACT_815880] 16 to 35 years, inclusive, at the time of screening  
2. The number of on -treatment pregnancies as assessed by [CONTACT_138969], t he method failure Pearl 
Index and the cumulative pregnancy rate in the overall study population  
4.2.2  Other Secondary Variables  
The other secondary variables are:  
1. Cycle control and bleeding patterns based on vaginal bleeding information recorded daily by [CONTACT_815881]  
2. Safety data in the overall study population obtained from routine laboratory parameters, vital signs, 
and physical, gynecological and breast examinations, evaluated as the number, frequency, type 
and intensity of AEs and SAEs  
3. Change f rom baseline to end of treatment in the different items of well -established questionnaires 
to evaluate physical, psychological, and social functioning and well -being  
4. Plasma E4 and DRSP concentration data from a subset of approximately 500 subjects for the 
development of a population PK model (Population PK Substudy). PK parameters will include, but 
not be limited to:  
a. Apparent clearance (CL/F).  
b. Central volume of distribution (V/F).  
c. Lag time of Absorption ( Tlag), if necessary.  
d. Maximum concentration (Cmax).  
e. Time to Cmax (Tmax).  
f. Extent of exposure for the dosing interval (AUCtau).  
g. Terminal half -life (t Â½). 
4.3 Predetermined Subgroups  
The key subgroup in this study is subjects aged 16 to 35 years, inclusive, at the time of screening. This 
subgroup is used for the prim ary efficacy population. All data regarding disposition, baseline characteristic s, 
compliance, exposure and contraceptive efficacy will be presented for subjects aged 16 to 35 years and for 
all subjects within the specified analysis population.  
In additio n, subgroup analyses will be performed for the Pearl Index and bleeding data (specifically 
unscheduled bleeding and spotting and the absence of scheduled bleeding) for the following categories:  
ï‚· Body Mass Index (BMI) categories (< 30, â‰¥ 30  kg/m2) at Baseline  
ï‚· Race category (White, Black or African American, Asian, American Indian or Alaska Native, Native 
Hawaiian or other Pacific Islander, Other Race)  
ï‚· Starters (including true new users)/ Switchers (see Section 5.5) 
Statis tical Analysis Plan  
Final  
Effective Date: 11-Dec-2018/Version 3.0 
Sponsor: Estetra  
Protocol no: MIT -Es0001 -C302  
PRS 005 T 17 E  Page 8 of 45 
Strictly Confidential. Â© 2004 -2014, PRA  Health Sciences. All rights reserved.  
ï‚· Smokers/Non -smokers at Baseline  
ï‚· Age ( â‰¥ 16 to â‰¤ 25; > 25 to â‰¤ 35 and > 35 years old) at Screening  
The non -smokers group includes subjects who are former smokers and never smokers. The smokers gro up 
includes subjects who are current smokers. The other race group includes subjects who selected more 
than one race or whose race was recorded as other race  on the CRF .  
Quality of life data will be presented for all subjects and for starters and switcher s separately.  
5.[ADDRESS_1129758] cycle will be 
derived from the data collected in the diary . 
If the conception is confirmed to be during a specific cycle in the narrative and this cycle is not in the diary 
data, then the cycle will be include d as cycle in the exposure for the derivation of the Pearl Index.  If the 
cycle in which conception occurred i s not known, cycle(s) up to the one in which the positive pregnancy 
test occurred will be included in the exposure for the derivation of the Pearl Index.  
For the analysis of bleeding data, the cycle will be shifted by 3 days with the 3 days of the next cycle 
included in the previous cycle. For example, in the bleeding analysis Cycle 2 will be from Day 4 of Cycle 2 
to Day 3 of Cycle 3 inclusive.   
The start and stop times of a cycle will be determined before determining whether the cycle is evaluable for 
the Pearl Index or evaluable for the bleeding data. Data review meetings may be held to determine if cycles 
are at-risk cycles  for the Pearl Index and if they are evaluable for the bleeding analysis prior to database 
lock (see Section 8.3) if the classification is not clear from  the data collected and the rules in the SAP .  
5.1.1  At-risk Cycle for Pearl Index   
In the  primary  calcul ation of the Pearl Index (see Section 9.5.1  for details)  and the Method failure Pearl 
Index , only at-risk cycles will be included in the derivation of the number of women -28 day equivalent cycles 
of treatment, which is used as the denominator. At-risk cycles will be defined as cycles in which the following 
criteria are both met: 
1. No other methods of birth control (including condoms and emergency contraception)  are used by 
[CONTACT_815878]  
2. The subject confirmed that sexual intercourse occurred during the cycle in the subject diary  
This definition of at-risk cycles will be used as the denominator for the Pearl Index for on -treatment 
pregnancies and also for on -treatment method failure pregnancies.  
Two alternative calculations of the exposure (i.e., the d enominator ) will be perfo rmed to allow  for 
comparisons with historical data : 
ï‚· All exposure,  which includes cycles with and without  other methods of birth control and cycles with 
and without sexual intercour se. In this derivation of the Pearl Index all cycles  are classed as at-
Statis tical Analysis Plan  
Final  
Effective Date: 11-Dec-2018/Version 3.0 
Sponsor: Estetra  
Protocol no: MIT -Es0001 -C302  
PRS 005 T 17 E  Page 9 of 45 
Strictly Confidential. Â© 2004 -2014, PRA  Health Sciences. All rights reserved.  
risk cycles with the exception of any cycles after the cycle of conception in the case of pregnancy . 
This denominator will be used for the Pearl Index for on -treatment pregnancies only , 
ï‚· Modified at-risk exposure, where only cycles with other methods of birth control are excluded, while 
occurrence  of sexual intercourse  is not taken into account . In this derivation of the Pearl Index, at-
risk cycles are defined as cycles in which no other methods of birth control (including condoms and 
emergency contraception)  are used by [CONTACT_815878].  
Two additional alternative definition s of at-risk cycles will be used for  the derivation of the Pearl Index for 
method failu re pregnancies . In the first of these definitions,  cycles q ualify if they meet all of the criteria 1 to 
8 listed below :  
1. No other methods of birth control (including condoms and emergency contraception)  are used by 
[CONTACT_815882] d iary 
2. The subject confirmed that sexual intercourse occurred during the cycle in the subject diary  
3. A subject does not have a user failure pregnancy with an estimated conception date in that cycle 
or prior to that cycle  and does not have a method failure pre gnancy with an estimated conception 
date prior to that cycle   
4. The subject does not receive unauthorized concomitant medication (see section [IP_ADDRESS] of the 
protocol) for at least one day during the cycle  
5. The subject  does not  miss [ADDRESS_1129759] had  no adverse events  of vomiting and/or diarrhea during the cycle  
In the s econd of these definitions, cycles qualify if they meet all of the criteria 1 and 3 to 8 listed above (i.e. 
occurrence of sexual intercourse is not taken into account),  
The following rules will be applied to all types of exposure :  
ï‚· If conception occurs in  a cycle, then that cycle will be included in the denominator , regardless of 
whether or not other  methods of birth control were used during that cycle , or whether or not sexual 
intercourse was confirmed .  
ï‚· If the conception is confirmed to be during a speci fic cycle in the narrative and this cycle is 
not in the diary data, then the cycle will be included  in the denominator , regardless of whether 
or not other methods of birth control were used during that cycle , or whether or not sexual 
intercourse was confir med  
ï‚· The only exception is for user failure pregnancies, which will be excluded from the exposure 
definitions based on the compliance rules 3 to 8 above, since they do not meet criterion 3  
ï‚· Cycles after the cycle of conception will be excluded from the deno minator  
ï‚· Missing data from the diary will be handled according to section 5.15.1 . 
5.1.2  Evaluable Cycle and Reference Period for Bleeding Data   
Bleeding data will be analyzed by [CONTACT_815883]  91-day reference period (RP) . For the analy sis of bleeding 
data by [CONTACT_5265] , the cycle will be shifted by [ADDRESS_1129760] non -missing response for bleeding  in Cycle 13  will be 
imputed.  
Statis tical Analysis Plan  
Final  
Effective Date: 11-Dec-2018/Version 3.0 
Sponsor: Estetra  
Protocol no: MIT -Es0001 -C302  
PRS 005 T 17 E  Page 10 of 45 
Strictly Confidential. Â© 2004 -2014, PRA  Health Sciences. All rights reserved.  
In determining whether a cycle is evaluable for the bleeding analysis of a specific population, the cycle 
based on the diary data will be used rather than the shifted cy cle used to present the data.  
For the ITT analysi s, a cycle wi ll be considered non -evaluable if:  
ï‚· The length of the cycle is longer than 28 days.  
A cycle will be considered non -evaluable  in the per -protocol (PP) analysis  for bleeding data  if any of the 
following criteria are met:  
1. A subject becomes pregnant in that cycle  or prior to that cycle  
2. The length of the cycle is shorter than [ADDRESS_1129761] a hormone -free period towards the end of the cycle  (i.e. there are not at 
least [ADDRESS_1129762] day an active tablet was taken in the next cycle)  
4. The subject received unauthorized  concomitant medication (see section [IP_ADDRESS]  of the protocol)  
thought to have the potential to impact the bleeding analysis  for at least one day during the cycle  
5. Use of unauthorized pre-treatment and  concomitant medication  thought to have the potential to 
impact the bleeding analysis , if cycle star ts within [ADDRESS_1129763] had a procedure to the vagina , cervix  or endometrium during the cycle  
A cycle with missing diary bleeding data will still be considered evaluable if the criteria above are not met 
and bleeding data can be impu ted for days with missing data (see Section 5.15.2 for details).  
Three other analyses of bleeding data will be pe rformed as follows:  
1. Using cycles in which all active pi[INVESTIGATOR_815802]. In this 
analysis, evaluable cycles will be defined as per the PP analysis but cycles where  there was  at 
least [ADDRESS_1129764] 2 missed active pi[INVESTIGATOR_4382] s 
between Day 1 and Day 24 are included . 
In addition, an analysis by [CONTACT_815884] 4 91-day RPs defined  as follows:  
ï‚· RP1 = Day 1  to Day 91  
ï‚· RP2 = Day 92 to Day 182  
ï‚· RP3 = Day 183 to Day 273  
ï‚· RP4 = Day [ADDRESS_1129765] day of Cycle 1.  
A RP will be considered to be non -evaluable in the ITT analysis when the RP is less than 91 days in duration 
(i.e. where the subject withdraws from the study during the RP). If there are any gaps between cycles in 
Statis tical Analysis Plan  
Final  
Effective Date: 11-Dec-2018/Version 3.0 
Sponsor: Estetra  
Protocol no: MIT -Es0001 -C302  
PRS 005 T 17 E  Page 11 of 45 
Strictly Confidential. Â© 2004 -2014, PRA  Health Sciences. All rights reserved.  
terms of date within the RP  (i.e. at the end of the [ADDRESS_1129766] active pi[INVESTIGATOR_815803]) , then the RP will be excluded from the ITT 
Population. For example, if Cy cle 1 Day 28 is 1 February 2018 and Cycle 2 Day 1 is 3 February, then RP1 
will be excluded from the ITT.   
A RP with missing bleeding diary data will still be considered evaluable if the criteri a above are not met and 
bleeding data can be imputed for days w ith missing data (see Section 5.15.2  for details).   
5.[ADDRESS_1129767] dose of study medication (regardless of whether this 
is an active  or inactive table), inclusive.  If the subject has a pregnancy after the first dose of study medication 
and prior to the last dose of study medication,  the On -Treatment Period is defined as the period of time 
between the date of first dose of study medicat ion and the date of the estimated date of conception , 
inclusive. If the subject has  a pregnancy when they are still on study medication but the estimated date of 
conception is missing because the date was not confirmed in an ultrasound, then the cycle and day of the 
estimated conception that is assigned from the narrative will be used to determine the end date.  
For TEAEs, the On -Treatment Period is defined as on or after  the date of first dose of study medication.  
For medications , the On -Treatment Period i s defined as the period of time between the date of first dose of 
study medication and the date of last dose of study medication (regardless of whether this is an active or 
inactive table), inclusive.  
If the subject had a period  of time when study medicat ion was not being taken between the date of first 
dose of study medication and the last dose of study medication, this time will still be considered to be during 
the On -Treatment Period.  
5.4 Body Mass Index  
BMI in kg/m2 will be calculated using the following f ormula:  
BMI=weight
height2 
Weight and height collected on the CRF will not be rounded prior to deriving BMI.  
5.[ADDRESS_1129768] never received a  hormonal contraceptive. This group of 
subjects is a subset of the group of subjects classed as starters.  
Statis tical Analysis Plan  
Final  
Effective Date: 11-Dec-2018/Version 3.0 
Sponsor: Estetra  
Protocol no: MIT -Es0001 -C302  
PRS 005 T 17 E  Page 12 of 45 
Strictly Confidential. Â© [ADDRESS_1129769] -Study Treatment  and Concomitant Medication Use  
Medications will be categorised as contraceptives and other medications that are not contra ceptives.  
For contraceptives, the medications will be classed as prior if :  
ï‚· The question â€œTaken prior to study?â€ on the eCRF is answered with Y  or 
ï‚· The medication start date is before the date of first dose of study medication   
The following contraceptive medications will be identified as concomitant  contraceptives : 
ï‚· Medications with a start date during the On -Treatment Period  for medications  (see Section 5.3 for 
details)  
ï‚· Medications with a start date prior to the date of first d ose of study medication and an end date 
after the date of first dose of study medication  
Any contraceptive s with a missing end date will be considered to be ongoing at the end of study treatment 
and thus would be assumed to be after the first dose of study  medication and therefore assigned as a 
concomitant contraceptive .  
Contraceptive medications can be classed as both prior and concomitant.  
Contraceptive s with a start date occurring after the end of the On -Treatment Period  for medications  will be 
identifi ed as post -study treatment contraceptive s. Contraceptives with a start date prior to the date of first 
dose of study medication and an end date on the same date as the date of first dose of study medication 
will be assumed to be prior only and not concomit ant.  
For other medications that are not contraceptives, m edications with an end date occurring before the date 
of first dose of study medication will be identified as prior medications.  
Medication s with a start date occurring after the end of the  On-Treatment Period  for medications  will be 
identified as post -study treatment medications.  
The following m edications  will be identified as concomitant medications:  
ï‚· Medications  with a start date during the  On-Treatment Period for medications (see Section 5.3 for 
details)   
ï‚· Medications with a start date prior to the date of first dose of study medication  and an end date on 
or after the date of first dose of study medication   
Any medications with a missing end date will be considered to b e ongoing at the end of study treatment 
and thus would be assumed to be after the first dose of study medication  and therefore assigned as a  
concomitant  medication .  
Medications  that are not contraceptives  cannot be classed as both prior and concomitant.  
5.[ADDRESS_1129770] been applied are included in the derivation of the 
endpoints in this Section by [CONTACT_5265].  
Statis tical Analysis Plan  
Final  
Effective Date: 11-Dec-2018/Version 3.0 
Sponsor: Estetra  
Protocol no: MIT -Es0001 -C302  
PRS 005 T 17 E  Page 13 of 45 
Strictly Confidential. Â© [ADDRESS_1129771] 
started . For each cycle, the total number of  pi[INVESTIGATOR_3353] (active or inactive) taken will be determined  from the subject 
diary . If an entry of the number of active  (pi[INVESTIGATOR_8745])  or inactive  (white)  pi[INVESTIGATOR_815804], then it will 
be assumed  that no pi[INVESTIGATOR_815805] . 
The compliance for a given cycle will be derived as  
100  ğ‘¥ ğ‘¡â„ğ‘’ ğ‘¡ğ‘œğ‘¡ğ‘ğ‘™  ğ‘›ğ‘¢ğ‘šğ‘ğ‘’ğ‘Ÿ  ğ‘ğ‘–ğ‘™ğ‘™ğ‘   ğ‘¡ğ‘ğ‘˜ğ‘’ğ‘›  ğ‘‘ğ‘¢ğ‘Ÿğ‘–ğ‘›ğ‘”  ğ‘¡â„ğ‘’ ğ‘ğ‘¦ğ‘ğ‘™ğ‘’
ğ‘¡â„ğ‘’ ğ‘›ğ‘¢ğ‘šğ‘ğ‘’ğ‘Ÿ  ğ‘œğ‘“ ğ‘ğ‘–ğ‘™ğ‘™ğ‘   ğ‘’ğ‘¥ğ‘ğ‘’ğ‘ğ‘¡ğ‘’ğ‘‘  ğ‘¡ğ‘œ ğ‘ğ‘’ ğ‘¡ğ‘ğ‘˜ğ‘’ğ‘›  ğ‘‘ğ‘¢ğ‘Ÿğ‘–ğ‘›ğ‘”  ğ‘¡â„ğ‘’ ğ‘ğ‘¦ğ‘ğ‘™ğ‘’ 
 
The number of pi[INVESTIGATOR_815806] â€“ start 
date of the cycle + [ADDRESS_1129772] dose of study medication â€“ the start 
date of the cycle o f interest + 1.   
In addition, the subject diary data will be used to identify when a pi[INVESTIGATOR_815807]. The number of 
missed pi[INVESTIGATOR_815808]. In this situation, a pi[INVESTIGATOR_815809] a day 
in the diary without a n entry for the number of tablets or with [ADDRESS_1129773] dose will be included in the derivation. The overall compliance will be determine d by [CONTACT_815885][INVESTIGATOR_3353] (active or inactive) taken across all cycles. The overall compliance will be calculated 
as 
100  ğ‘¥ ğ‘¡â„ğ‘’ ğ‘¡ğ‘œğ‘¡ğ‘ğ‘™  ğ‘›ğ‘¢ğ‘šğ‘ğ‘’ğ‘Ÿ  ğ‘œğ‘“ ğ‘ğ‘–ğ‘™ğ‘™ğ‘   ğ‘¡ğ‘ğ‘˜ğ‘’ğ‘›  ğ‘ğ‘ğ‘Ÿğ‘œğ‘ ğ‘   ğ‘ğ‘™ğ‘™ ğ‘ğ‘¦ğ‘ğ‘™ğ‘’ğ‘ 
ğ‘¡â„ğ‘’ ğ‘‘ğ‘ğ‘¡ğ‘’  ğ‘œğ‘“ ğ‘™ğ‘ğ‘ ğ‘¡  ğ‘‘ğ‘œğ‘ ğ‘’ âˆ’ğ‘¡â„ğ‘’ ğ‘ ğ‘¡ğ‘ğ‘Ÿğ‘¡  ğ‘‘ğ‘ğ‘¡ğ‘’  ğ‘œğ‘“ ğ‘ğ‘¦ğ‘ğ‘™ğ‘’  1+[ADDRESS_1129774] dose date â€“ the first dose date + 1.  
The last dose date will be the date the last tablet was taken regardless of whether this is an active or inactive 
tablet.  The total extent of exposure across all subjects  in years  will be derived b y summing the total 
exposure in days across all subjects in the Safety Population  and dividing it by 365.25 to convert the units 
Statis tical Analysis Plan  
Final  
Effective Date: 11-Dec-2018/Version 3.0 
Sponsor: Estetra  
Protocol no: MIT -Es0001 -C302  
PRS 005 T 17 E  Page 14 of 45 
Strictly Confidential. Â© [ADDRESS_1129775] diary  and the pregnancy narrative completed by [CONTACT_978]  [INVESTIGATOR_815810] a compliant (Product Failure) or non -compliant (User -Failure) subject with 
compliance su ggesting method  failure and non -compliance suggesting  user failure. The definitions of pre -
, on- and post -treatment pregnancies and for method and user failure pregnancies are provided below.  
5.9.[ADDRESS_1129776] dose of study medication.  
5.9.2  On-Treatment Pregnancies  
On-treatment pregnancies are pregnancies with an estimated date of conception during the On-Treatment 
Period  for contraceptive efficacy  (see Section 5.3 for the definition of the On -Treatment Period) . In cases 
where the date of conception cannot be established unequivocally (e.g. subjects is lost to follow up), this 
pregnancy will be considered as on -treatment  pregnancy.   
For on -treatment pregnancies, the cycle and day  within the cycle  of conception will be assigned based on 
the diary data collected and the estimated conception date. If the on -treatment pregnancy has an estimated 
date of conception in the [ADDRESS_1129777] the  potential  to trigger interactions with COC  (Section 9.4.6 of the Protocol) . 
Pregnancies not identified as due to user failure will be considered to be method failure pregnancies.  The 
pregnancy narratives from the P rincipal Investigator  are used to determine whether a pregnancy is a user 
or method failure pregnancy.  
Statis tical Analysis Plan  
Final  
Effective Date: 11-Dec-2018/Version 3.0 
Sponsor: Estetra  
Protocol no: MIT -Es0001 -C302  
PRS 005 T 17 E  Page 15 of 45 
Strictly Confidential. Â© [ADDRESS_1129778] diary data will be used to characterize bleeding patterns.  Bleeding data will be analyzed by 
[CONTACT_815886] . 
5.10.1  Definitions of Bleeding and Spotting  
Definitions for bleeding and spotting used for the cycle and RP analysis are provided in Table 1 below . In 
the diary, â€œ0â€ was to be ticked  for no bleeding or spotting, â€œ1â€ for spo tting and â€œ2â€ for bleeding.  
Table 1: Bleeding and spotting definitions  
Term  Definition  
Bleeding  Evidence of vaginal blood loss that requires the use of sanitary protection with a 
tampon, pad or pantyliner . 
Spotting  Evidence of min imal vaginal  blood loss that does not require new use of sanitary 
protection, including pantyliners . 
Bleeding day  Day where bleeding  (2) was reported for that day in the subject diary  
Spotting da y Day where spotting (1) was reported for that day in the s ubject diary  
Bleeding/spotting -
free day Day where no bleeding or spotting (0) was reported in the subject diary  
 
Bleeding/Spotting  
epi[INVESTIGATOR_815811] b leeding  and/or spotting days  where there are both 
bleeding and spotting days  bounded on ei ther end by 2 bleeding/spotting -free 
days  
Bleeding only 
epi[INVESTIGATOR_815812] 2 bleeding /spotting -free days  
Spotting only 
epi[INVESTIGATOR_815813] e there are no bleeding days  bounded 
on either end by 2 bleeding/ spotting -free days  
Bleeding/spotting -
free epi[INVESTIGATOR_815814]/spotting -free days bounded on either end by a 
bleeding  or spotting day  
 
5.10.2  Cycle analysis  
[IP_ADDRESS]  Definition of cycle s 
In the  cycle analysis of a 24/[ADDRESS_1129779] inactive tablet  (Day 25) and end on Day 3 of the next cycle  (expected bleeding 
period) . In principle, no vaginal bleedin g is expected to occur at other times during the cycle. This means 
that the remainder of the cycle constituted the expected non -bleeding period of 21 days. Therefore, any 
bleeding/spotting that occur s during the expected non -bleeding period (starting on Da y 4 of the actual cycle 
up to and including Day 24 ) are considered as unscheduled.  
The following definitions ( Table 2) will be used for the cycle analysis:  
Statis tical Analysis Plan  
Final  
Effective Date: 11-Dec-2018/Version 3.0 
Sponsor: Estetra  
Protocol no: MIT -Es0001 -C302  
PRS 005 T 17 E  Page 16 of 45 
Strictly Confidential. Â© 2004 -2014, PRA  Health Sciences. All rights reserved.  
Table 2: Bleeding/spotting definit ions used for the cycle analysi s 
Scheduled 
Bleeding/Spotting 
(Withdrawal 
Bleeding /Spotting ) Any bleeding/spotting that occurs during the hormone -free interval (i.e. Days 25 
â€“ 28) and continues through Days 1 -3 of the subsequent active cycle.  
Note: any blee ding/spotting that occurs while taking active hormones during 
Days [ADDRESS_1129780] cycle will be imputed as no bleeding.  
Unscheduled 
Bleeding/Spotting  Any bleeding /spotting  that occurs while taking active hormones  that does not 
meet the criteria for sche duled bleeding/spotting . 
Unscheduled 
Bleeding  Any bleeding that occurs while taking active hormones that does not meet the 
criteria for scheduled bleeding . 
Unscheduled 
Spotting  Any spotting that occurs while taking active hormones that does not meet the 
criteria scheduled spotting . 
Early Withdrawal 
Bleeding/Spotting  Any bleeding/spotting epi[INVESTIGATOR_815815]/spotting 
period and continues into the scheduled bleeding/spotting period . 
Continued 
withdrawal 
bleeding /spotting  Any bleeding/spotting epi[INVESTIGATOR_815816]/spotting 
period and continues after the scheduled bleeding/spotting period . 
 
  
Based on th ese definition s, the cycle analysis of bleeding/spotting epi[INVESTIGATOR_815817]:  
ï‚· a classic al approach  
ï‚· a modified cycle analysi s  
[IP_ADDRESS]  Classical cycle analysis  
In the classical analysis,  early and continued withdrawal bleeding are regarded  as scheduled.  
The following  rules will be used for the classical approach  to classify each bleeding only epi[INVESTIGATOR_1865] , spotting 
only epi[INVESTIGATOR_815818]/ spotting epi[INVESTIGATOR_815819] : 
The epi[INVESTIGATOR_815820] , if any of the following criteria are met:  
ï‚· The epi[INVESTIGATOR_815821] a start date after Day 7 of Cycle 1 and an end date that is on or before Day  24 of 
Cycle 1  
ï‚· For Cycles 2 to 13, the epi[INVESTIGATOR_815821] a start date after Day 3 of the cycle and an end date that is on 
or before Day 24 of the cycle  
The epi[INVESTIGATOR_815822]  (withdrawal bleeding and/or spotting), if any of the following criteri a 
are met: 
ï‚· The epi[INVESTIGATOR_815821] a start date after Day 24 of the cycle and an end date that is on or before Day 3 
of the next cycle  
ï‚· The epi[INVESTIGATOR_815821] a start date after Day 24 of the cycle and an end date that is  after Day 3 of the 
next cycle  (continued withdrawal bl eeding/spotting) .  
o Note it is not possible to have continued withdrawal bleeding for Cycle 13 because data 
are not collected for Cycle 14  
ï‚· The epi[INVESTIGATOR_815821] a start date before Day 24 of the cycle and an end date on or after Day 25 (early 
withdrawal bleeding/ spotting) . 
Statis tical Analysis Plan  
Final  
Effective Date: 11-Dec-2018/Version 3.0 
Sponsor: Estetra  
Protocol no: MIT -Es0001 -C302  
PRS 005 T 17 E  Page 17 of 45 
Strictly Confidential. Â© 2004 -2014, PRA  Health Sciences. All rights reserved.  
All bleeding days  and spotting days  will then be classified as scheduled or unscheduled  based on whether 
the bleeding or spotting days are included in a scheduled or unscheduled epi[INVESTIGATOR_815823] . A bleeding day  or spotting day that occurs in a scheduled epi[INVESTIGATOR_815824] a bleeding day or spotting day that occurs in an unscheduled epis ode will be classified as 
unscheduled .  
[IP_ADDRESS]  Modified Cycle Analysis  
In the modified cycle analysis, the definiti ons of expected non -bleeding and expected bleeding periods  are 
strictly followed, i.e., all bleeding epi[INVESTIGATOR_815825] -bleeding intervals are considered 
unscheduled. Thus in this analysis , the definitions of scheduled and unscheduled bleeding/spotting 
epi[INVESTIGATOR_815826] 2 are also applicable , but early and continued withdrawal bleedings are 
regarded as unscheduled.  
Therefore,  in the derivation of endpoints where early and continued withdrawal bleeding are classed as 
unsche duled  bleeding the following rules are used  to classify each bleeding only epi[INVESTIGATOR_1865], spotting only 
epi[INVESTIGATOR_815818]/ spotting epi[INVESTIGATOR_815819] :  
The epi[INVESTIGATOR_815820] , if any of the following criteria are met:  
ï‚· The epi[INVESTIGATOR_815827] a start date after Day 7 of Cycle 1 and an end date that is on or before Day 24 of 
Cycle 1  
ï‚· For Cycles 2 to 13, the epi[INVESTIGATOR_815821] a start date after Day 3 of the cycle and an end date that is on 
or before Day 24 of the cycle  
ï‚· The epi[INVESTIGATOR_815821] a start dat e after Day 24 of the cycle and an end date that is  after Day 3 of the 
next cycle  (continued withdrawal bleeding/spotting)   
o Note it is not possible to have continued withdrawal bleeding for Cycle 13 because data 
are not collected for Cycle 14  
ï‚· The epi[INVESTIGATOR_1865] h as a start date before Day 24 of the cycle and an end date that is on or after Day 25 
(early withdrawal bleeding/spotting)  
The epi[INVESTIGATOR_815822]  (withdrawal bleeding and/or spotting), if the following criterion is met:  
ï‚· The epi[INVESTIGATOR_815821] a start  date after Day [ADDRESS_1129781] as 
outlined for the classical analysis but using the rules in this Section above  where early and continued 
withdrawal bleeding are classed as unscheduled epi[INVESTIGATOR_1841] .  
5.10.3  Reference Periods (RPs)  
No additional definitions  other than those displayed in Table [ADDRESS_1129782], 
missing data rules are provided in Section 5.15.2  and definitions of terminology are provided in Section 
5.10.1  and 5.10.2 .  
Depending on the a pproach used for the cycle analysis (the classical approach versus the modified cycle 
analysis), f or each evaluable cycle for each subject, the following  will be determined : 
ï‚· Whether there was at least one unscheduled bleeding only,  spotting  only or bleedin g/spotting  
epi[INVESTIGATOR_815828]  (see Section 5.10.2  for definition) . It will be assumed that there is at least 
Statis tical Analysis Plan  
Final  
Effective Date: 11-Dec-2018/Version 3.0 
Sponsor: Estetra  
Protocol no: MIT -Es0001 -C302  
PRS 005 T 17 E  Page 18 of 45 
Strictly Confidential. Â© 2004 -2014, PRA  Health Sciences. All rights reserved.  
one unscheduled epi[INVESTIGATOR_815829] t 
ï‚· Whether there was at least one unscheduled bleeding only epi[INVESTIGATOR_815828] (see Section 
5.10.2  for definition)  and no unscheduled bleeding/spotting epi[INVESTIGATOR_815830] . It will be assume d that there is at least one unscheduled  bleeding only  epi[INVESTIGATOR_815831]  
ï‚· Whether there was at least one unscheduled spotting  only epi[INVESTIGATOR_815828] (see Se ction 
5.10.2  for definition)  and no unscheduled bleeding/spotting epi[INVESTIGATOR_815832] . It will be assumed that there is at least one unscheduled  spotting  only epi[INVESTIGATOR_815833]  
ï‚· Whether there is an absence of any bleeding or spotting (i.e. all days in the cycle are 
bleeding/spotting -free days)  
ï‚· Whether there is an absence of scheduled bleeding only, spotting  only and bleeding/spotting  
epi[INVESTIGATOR_1865] s (i.e. there is no scheduled epi[INVESTIGATOR_56170] a start date during that cycle of interest )  
ï‚· Whether there is early withdrawal bleeding  or spotting  in that cycle (i.e. there is  either an  early 
withdrawal  bleeding only, spottin g only or bleeding/spotting epi[INVESTIGATOR_815834])  
ï‚· Whether there is continued withdrawal bleeding  or spotting  in that cycle (i.e. there is either a 
continued withdrawal bleeding only, spotting only or bleeding/spotting epi[INVESTIGATOR_815835])   
ï‚· The total (scheduled + unscheduled) number of days with bleeding and/or spotting  (i.e. the number 
of bleeding days + the number of spotting days  within the bleeding only, spotting only and 
bleeding/spotting epi[INVESTIGATOR_815836] ) 
ï‚· The total (scheduled + unscheduled) number of days with bleeding only (i.e. the number of bleeding 
days within the bleeding only and bleeding/spotting epi[INVESTIGATOR_815837])  
ï‚· The total (sc heduled + unscheduled) number of days with spotting only (i.e. the number of spotting 
days within the spotting only and bleeding/spotting epi[INVESTIGATOR_815837])  
ï‚· The number of unscheduled days with bleeding and/or spotting (i.e. t he number of bleeding days 
+ the number of spotting days  within the unscheduled bleeding only, spotting only and 
bleeding/spotting epi[INVESTIGATOR_815837] )  
ï‚· The number of unscheduled days with bleeding only (i.e. the number of blee ding days within the 
unscheduled bleeding only and bleeding/spotting epi[INVESTIGATOR_815837])  
ï‚· The number of unscheduled days with spotting only  (i.e. the number of spotting days within the 
unscheduled spotting only and bleeding/spo tting epi[INVESTIGATOR_815837])   
ï‚· The number of scheduled days with bleeding and/or spotting (i.e. the number of bleeding days + 
the number of spotting days  within the scheduled bleeding only, spotting only and bleeding/spotting 
epi[INVESTIGATOR_815837] )  
ï‚· The number of scheduled days with bleeding only  (i.e. the number of bleeding days within the 
scheduled bleeding only and bleeding/spotting epi[INVESTIGATOR_815837])  
ï‚· The number of schedu led days with spotting only (i.e. the number of spotting days within the 
scheduled spotting only and bleeding/spotting epi[INVESTIGATOR_815837])  
ï‚· The start da y for any scheduled bleeding epi[INVESTIGATOR_815838] a start date within the cyc le (if there 
are more than one scheduled bleeding epi[INVESTIGATOR_815839], then only the start day of the earliest  
epi[INVESTIGATOR_815840] )  
Statis tical Analysis Plan  
Final  
Effective Date: 11-Dec-2018/Version 3.0 
Sponsor: Estetra  
Protocol no: MIT -Es0001 -C302  
PRS 005 T 17 E  Page 19 of 45 
Strictly Confidential. Â© [ADDRESS_1129783]:  
ï‚· The total number of days with bleeding and/or spotting  (i.e. the number of bleeding days + the 
number of spotting days within the bleeding only, spotting only and bleeding/spott ing epi[INVESTIGATOR_815841])   
ï‚· The total number of days with bleeding only (i.e. the number of bleeding days within the 
bleeding only and bleeding/spotting epi[INVESTIGATOR_815842])  
ï‚· The total number of days with sp otting only (i.e. the number of spotting days within the spotting 
only and bleeding/spotting epi[INVESTIGATOR_815842])  
ï‚· The number of bleeding and/or spotting epi[INVESTIGATOR_1841]  
ï‚· The mean duration of the bleeding and/or spotting  epi[INVESTIGATOR_1841]  
ï‚· The numbe r of bleeding and/or spotting free epi[INVESTIGATOR_1841]  
ï‚· The mean duration of the bleeding and/or spotting free epi[INVESTIGATOR_815843]/or spotting epi[INVESTIGATOR_815844], the number of epi[INVESTIGATOR_815845]  + the num ber of spotting only epi[INVESTIGATOR_1841] + the number of spotting/bleeding 
epi[INVESTIGATOR_815846] a start date during that RP. The duration of an epi[INVESTIGATOR_815847] â€“ start date of the epi[INVESTIGATOR_1865] + 1. The mean duration of epi[INVESTIGATOR_815848] a start date during that RP. The full duration of each of the epi[INVESTIGATOR_815849], even if the epi[INVESTIGATOR_815850].  
5.11 Treatment -Emergent Adverse Event (TEAE ) 
A TEAE is defined as an AE with a start date  or worsening  during the On -Treatment Period for TEAEs (see 
Section 5.3 for definition of the On -Treatment Period) . 
If the start date for an AE is missing and the end date is either  missing or on or after the date of first dose 
of study medication, then the AE will be assumed to be treatment -emergent. However, if the start date for 
an AE is missing and the end date is recorded and is before the first dose of study medication, then th e AE 
will be assumed to be non -treatment emergent.  
5.12 Quality of Life Enjoyment and Satisfaction Questionnaire Short Form (Q -
LES-Q-SF) 
The total score of the Q -LES-Q-SF (see Appendix 4 of the Protocol) will be derived by [CONTACT_815887] 14 
items to obtain t he raw total score. The raw total score is then transformed into a percentage maximum 
using the following formula:  
ğ‘ƒğ‘’ğ‘Ÿğ‘ğ‘’ğ‘›ğ‘¡ğ‘ğ‘”ğ‘’  ğ‘€ğ‘ğ‘¥ğ‘–ğ‘šğ‘¢ğ‘š =(ğ‘Ÿğ‘ğ‘¤  ğ‘¡ğ‘œğ‘¡ğ‘ğ‘™  ğ‘ ğ‘ğ‘œğ‘Ÿğ‘’  â€“ 14)
56 
In the case of questions with missing results, if  10 or more que stions are answered, then  the percentage 
maximum is derived as follows:  
  
ğ‘ƒğ‘’ğ‘Ÿğ‘ğ‘’ğ‘›ğ‘¡ğ‘ğ‘”ğ‘’  ğ‘€ğ‘ğ‘¥ğ‘–ğ‘šğ‘¢ğ‘š =(ğ‘Ÿğ‘ğ‘¤  ğ‘¡ğ‘œğ‘¡ğ‘ğ‘™  ğ‘ ğ‘ğ‘œğ‘Ÿğ‘’  ğ‘“ğ‘œğ‘Ÿ ğ‘¡â„ğ‘’ ğ‘ğ‘¢ğ‘’ğ‘ ğ‘¡ğ‘–ğ‘œğ‘›ğ‘   ğ‘ğ‘›ğ‘ ğ‘¤ğ‘’ğ‘Ÿ  â€“ ğ‘›ğ‘¢ğ‘šğ‘ğ‘’ğ‘Ÿ  ğ‘œğ‘“ ğ‘ğ‘¢ğ‘’ğ‘ ğ‘¡ğ‘–ğ‘œğ‘›ğ‘   ğ‘ğ‘›ğ‘ ğ‘¤ğ‘’ğ‘Ÿ )
(ğ‘¡â„ğ‘’ ğ‘›ğ‘¢ğ‘šğ‘ğ‘’ ğ‘Ÿ ğ‘œğ‘“ ğ‘ğ‘¢ğ‘’ğ‘ ğ‘¡ğ‘–ğ‘œğ‘›ğ‘   ğ‘ğ‘›ğ‘ ğ‘¤ğ‘’ğ‘Ÿğ‘’ğ‘‘  Ã— 4) 
If fewer than 10 questions are answered, then the percentage maximum will be considered to be missing.  
Statis tical Analysis Plan  
Final  
Effective Date: 11-Dec-2018/Version 3.0 
Sponsor: Estetra  
Protocol no: MIT -Es0001 -C302  
PRS 005 T 17 E  Page 20 of 45 
Strictly Confidential. Â© [ADDRESS_1129784].  
5.13 Menstrual Distres s Questionnaire   
The Menstrual Distress Questionnaire  (see Appendix 5 of the Protocol)  will be scored according to the 
manual  (Moos, 1968 ). The following scales will be derived by [CONTACT_815888]: pain, water retention, autonomic reactions, negative affect, impaired concentration, 
behavior change, arousal and control. Each of these are derived at each visit for the menstrual (most recent 
flow in CRF), premenstrual (4 days before in th e CRF) and intermenstrual (remainder of the cycle in the 
CRF) phases by [CONTACT_815889]. The scoring key is presented in 
Table [ADDRESS_1129785].  
Table 3: Menstrual Distress Questionnaire Scoring Key  
Scale  Items  
Pain 1, 2, 3, 4, 5, [ADDRESS_1129786] dose of study medication to the 
return to menstruation will be calculated as the date of return of menses â€“ the date of last dose of study 
medication.  If the subjectâ€™s fertility information indicates that she had confirmation of pregnancy, then time 
from last dose of study medication to the estimated date of conception  will be calculated as the estimated 
date of conception  â€“ the date of last dose of stud y medication.  The estimated date of conception will be 
derived as the date of expected pregnancy term â€“ 38 weeks  (266 days) . If the subjectâ€™s fertility information 
indicates that she received a new contraceptive method, then time from last dose of study me dication to 
the date of the new contraceptive method will be calculated as the date of new contraceptive method â€“ the 
date of last dose of study medication.  
5.[ADDRESS_1129787] diary, it will be assumed that she did not 
Statis tical Analysis Plan  
Final  
Effective Date: 11-Dec-2018/Version 3.0 
Sponsor: Estetra  
Protocol no: MIT -Es0001 -C302  
PRS 005 T 17 E  Page 21 of 45 
Strictly Confidential. Â© [ADDRESS_1129788] sexual intercourse and that cycle will be classed as a not at-risk cycle and excluded  from the 
denominator of the Pearl Index  as appropriate . 
For compliance, i f the number of active (pi[INVESTIGATOR_8745]) and inactive (white) pi[INVESTIGATOR_815851], then it will be 
assumed that no pi[INVESTIGATOR_815852].  
If there is a partial start date for a c ycle, then the start date will be imputed as the day after the date of Day 
[ADDRESS_1129789] ied:  
ï‚· If the end date is before the first dose of study medication, then the medication is a prior medication, 
regardless of whether or not the start date is missing or partially missing  
ï‚· If the end date is on or after the date of first dose of study medic ation, then the following rules will 
be applied for missing or partially missing start dates:  
o If the start date is completely missing, then the medication will be assumed to be 
concomitant.  
o If only the year of the start date is recorded and the year is eit her before or the same year 
as the end of the safety On -Treatment Period, then the medication will be assumed to be 
concomitant.  
o If only the year of the start date is recorded and the year is after the year of the end of the 
safety On -Treatment Period, it  will be considered to be a post -study treatment medication.  
o If only the year and the month of the start date is recorded and the month specified is either 
before or the same month as the end of the safety On -Treatment Period, then the 
medication will be assumed to be concomitant  
o If only the year and the month of the start date is recorded and the month specified is after 
the month of the end of the safety On -Treatment Period, it will be considered to be a post -
study treatment medication.  
Statis tical Analysis Plan  
Final  
Effective Date: 11-Dec-2018/Version 3.0 
Sponsor: Estetra  
Protocol no: MIT -Es0001 -C302  
PRS 005 T 17 E  Page 22 of 45 
Strictly Confidential. Â© [ADDRESS_1129790] dose of study medication, then the AE 
will b e assumed to be non -treatment emergent.  
Rules for dealing with missing start and stop dates for study medication for the classification of AEs are in 
Section 5.15.5 . 
5.15.5  Missing  or Partial  Treatment Start and Stop Dates  
[IP_ADDRESS]  Missing Tre atment Start and Stop Dates  
If the subject has no diary data but has a pregnancy as per P rincipal Investigatorâ€™s  assessment in the 
pregnancy narrative that is classified as on -treatment or post treatment, then the subject will be classed as 
treated. The treatment start date and treatment stop date would be unknown in this situation.  
In the case of post -treatment pregnancies, the cycle for censoring for the cumulative event rates for 
pregnancies  cannot be determined and this will be missing. The subject wil l also consequently have no 
evaluable cycles for the Pearl Index. In the case of on-treatment pregnancies, the cycle of conception from 
the narrative will be used in the derivation of the cumulative event rates for pregnancies and in the derivation 
of the Pearl Index but for the Pearl Index no other cycles would be included in the denominator for that 
subject.  
When classifying concomitant , pre - and post medication and treatment emergent AEs  and defining the 
Baseline assessments , the treatment start date wi ll be assumed to be the first date in which the 
investigational product was dispensed and the treatment end date will be assumed to be the discontinuation 
or completion date for that subject. However, the start and stop dates for study medication will  rema in 
missing and  the compliance  and exposure will not be calculated. Similarly, the cycle of discontinuation of 
study medication cannot be determined and therefore this would remain missing for such subjects. The 
subject will have no evaluable cycles for the  bleeding analysis.  
[IP_ADDRESS]  Partial Treatment Start Dates  
If the subject has a partial start date Cycle [ADDRESS_1129791] dose.  The diary data for pi[INVESTIGATOR_815853].  
Statis tical Analysis Plan  
Final  
Effective Date: 11-Dec-2018/Version 3.0 
Sponsor: Estetra  
Protocol no: MIT -Es0001 -C302  
PRS 005 T 17 E  Page 23 of 45 
Strictly Confidential. Â© 2004 -2014, PRA  Health Sciences. All rights reserved.  
6.0 Analysis Sets  
6.1 Screened Population  
The Screened Population includes all subjects who signed an  informed consent  (IC) form.  
The Screened Population will be used for disposition data and data will be displayed for subjects aged 1 6 
to 35 yea rs and for all subjects in separate columns.  
6.2 Enrolled Population  
The Enrolled Population includes all enrolled subjects  (i.e. subjects who had a non -missing enrollment date 
on the enroll ment page of the  CRF) . 
The Enrolled Population will be used for summar ies of enrollment per country.  
6.[ADDRESS_1129792] has a pregnancy that is classified as per P rincipal Investigatorâ€™s  assessment in the 
pregnancy narrative as either an on -treatment or post treatment pregn ancy, then the subject will be included 
in the Safety Population. In the case of missing diary data, it will be assumed that no pi[INVESTIGATOR_815854]. If there was at least one pi[INVESTIGATOR_815855], then that subject will be 
included in the Safety Population.   
The Safety Population will be used for compliance  and exposure  data with data displayed for subjects aged 
16 to 35 years and for all subjects in separate columns. The Safety Population will also be  used for safety 
presented for all subjects.  
Follow -up evaluations will be presented for subjects in the Safety Population who discontinued study 
medication with pregnancy wi sh as the reason for discontinuation.  
6.4 Intention -to-Treat (ITT) Population  
The ITT Population includes all enrolled subjects who receive at least one dose of study medication . The 
ITT Population is the same as the Safety Population for this study.  
The ITT P opulation will be used for baseline and contraceptive efficacy data with data displayed for 
subjects aged 16 to 35 years  and for all subjects in separate columns. The ITT Population will also be 
used for  protocol deviations,  bleeding and quality of life da ta with data presented for all subjects.   
6.5 Per-Protocol (PP) Population  
The bleeding data  cycle analysis  will be presented in the PP Population. For the bleeding analysis, the PP 
Population will exclude cycles based on the rules in Section 5.1.[ADDRESS_1129793] no evaluable cycles for the bleeding analysis.  
6.6 Pharmacokinetics (PK) Population  
The PK Population includes all subjects enrolled in the PK Substudy who provide concentration data for at 
least one sample.  
Statis tical Analysis Plan  
Final  
Effective Date: 11-Dec-2018/Version 3.0 
Sponsor: Estetra  
Protocol no: MIT -Es0001 -C302  
PRS 005 T 17 E  Page 24 of 45 
Strictly Confidential. Â© 2004 -2014, PRA  Health Sciences. All rights reserved.  
The PK Population will be used for all PK analysis described in Section 9.8. 
7.0 Interim Analyses  
There are no planned interim analyses for this study.  
8.0 Data Review  
8.1 Data Handling and Transfer  
Processes for data handling and transfer w ill be documented in the  Data Management Plan.  
8.2 Data Screening  
Beyond the data screening built into the PRA Data Management Plan, the PRA programming of analysis 
datasets, tables, figures, and listings (TFL) provides additional data screening. Presumed data  issues will 
be output into SAS logs identified by [CONTACT_100328] â€œProblemâ€ and extracted from the logs by a SAS macro and 
sent to Data Management.  
Review of a pre -freeze TFL run on clean subjects and a post -freeze TFL run on the frozen database allow 
for furthe r data screening prior to lock. The post -freeze TFL will be discussed with the sponsor in a data 
review meeting to identify any final data issues and seek corrections prior to database lock. The PRA 
statistician and the sponsor must approve database lock.  
8.3 Data Review Meetings  
Data review meetings will be held during the course of the study prior to database lock and the following 
may be reviewed during these meetings:  
ï‚· Important protocol deviations and exclusion from the PP Population  
ï‚· Classification of at-risk and not at-risk cycles for the Pearl Index derivation  where the classification 
is not clear based on the data collected and the rules in the SAP  
ï‚· Classification of on -, pre- and post - treatment pregnancies for the Pearl Index derivation  
ï‚· Classification of  method failure and user failure pregnancies for the method failure Pearl Index 
derivation  
ï‚· Classification of evaluable and non -evaluable cycles for the PP bleeding analysis where the 
classification is not clear based on the data collected and the rules in the SAP  
9.0 Statistical Methods  
All analyses will be conducted using SAS version 9.4 or higher.  
No formal statistical analyses will be performed  in this study . 
The following conventions will be used when presenting summary statistics for study data:  
ï‚· Continuous  variables will be summarized using the following descriptive statistics: number of 
subject s (n), mean, standard deviation (SD),  standard error of the mean (SEM),  median, minimum 
(min), maximum (max) , 25th percentile (lower quartile or Q1) and 75th percent ile (upper quartile or 
Q3) 
ï‚· Categorical and count variables will be summarized by [CONTACT_14458] (n) and the percent 
of subjects in each category.  For AE tables, m may also be presented which represents the number 
of events.  Percentages will be pres ented to [ADDRESS_1129794]  
Statis tical Analysis Plan  
Final  
Effective Date: 11-Dec-2018/Version 3.0 
Sponsor: Estetra  
Protocol no: MIT -Es0001 -C302  
PRS 005 T 17 E  Page 25 of 45 
Strictly Confidential. Â© 2004 -2014, PRA  Health Sciences. All rights reserved.  
ï‚· The number of subjects or observations will be presented as an integer  
ï‚· Mean , median , lower quartile and upper quartile  will be presented to [ADDRESS_1129795] more than the 
raw value  
ï‚· Min and max will be presented to the same number of  decimal places as the raw value  
ï‚· Standard deviation will be presented to 2 decimal places more than the raw value, up to a 
reasonable number of decimal places (i.e., rarely more than 3 decimal places unless the nature of 
the data suggests this)  
ï‚· The denomin ator for percentage calculations will be the number of non -missing observations at 
that visit. Where this isnâ€™t appropriate, the number of subjects in the relevant population will be used  
9.[ADDRESS_1129796] treatment pregnancy based on the  Principal Investigatorâ€™s  
assessment in the pregnancy narrative , then the subject will be  classed as treated . In the case of missing 
diary data, it will be assumed that no pi[INVESTIGATOR_815856]. If there 
was at least one pi[INVESTIGATOR_815857], then that subject will be classed as treated.   
Tabulations of the number and percentage of subjects included in each analysis set will be provided.  The 
percentage will not be presented for the Screened and Enrolled Populations . Percentages will be derived 
based on the number of subjects enrolled.  
A tabulation of the number and percentage of subjects  enrolled at each site and country  will be summariz ed 
in the Enrolled Population . 
Disposition data and the site and country will be  listed  in the Enrolled Population . Information on inclusion 
in each of the analysis sets will be listed in the Screened Population.  Screening failures will be listed with 
the reason for the screening failure.  
The cumulative discontinuation rate, as determ ined by [CONTACT_81428] -table methods, together with the corresponding 
95% CIs will be presented in the ITT population for all subjects and for subjectâ€™s aged [ADDRESS_1129797] in SAS where the time variable is the cycle where the 
discontinuation occurred for subjects who discontinued from the study prematurely. Subjects who did not 
discontinue from the study prematurely will be censored in Cycle 13. The rate of discontinuation and 95% 
CIs will be calculated based on Kaplan -Meier estimates for each cycle. Additionally, the estimated survival 
function against time (cycle) will be provided.   
9.2 Protocol Deviations and Violation s 
The important protocol deviations for this study will be specified in the Protocol Deviation Guidance 
Template. Per PRA processes, protocol deviations will be entered into PRAâ€™s Clinical Trials Management 
System (CTMS). The study team and the sponsor wil l conduct ongoing reviews of the protocol deviation s 
from CTMS to identify deviations which meet the criteria for important.  
Statis tical Analysis Plan  
Final  
Effective Date: 11-Dec-2018/Version 3.0 
Sponsor: Estetra  
Protocol no: MIT -Es0001 -C302  
PRS 005 T 17 E  Page 26 of 45 
Strictly Confidential. Â© [ADDRESS_1129798] -freeze data review meeting (or earlier), prior to database lock.  
9.[ADDRESS_1129799] 1, 2, 3, etc. cycles will be summarized.  
Exposure data will be listed for all subjects in the Safety Population.  
9.3.2  Treatment Compliance  
Treatment compliance by [CONTACT_815890]:  
ï‚· The number of pi[INVESTIGATOR_38947]  
ï‚· The compliance   
The number and percentage of subjects missing no pi[INVESTIGATOR_3353], [ADDRESS_1129800] -study treatment  and concomitant medications will be listed  in the Safety Population . 
9.4 Demographic and Baseline Characteristics  
All summaries described in this Section will be presented for subjects aged 16 to 35 years  and for all 
subjects.  
Statis tical Analysis Plan  
Final  
Effective Date: 11-Dec-2018/Version 3.0 
Sponsor: Estetra  
Protocol no: MIT -Es0001 -C302  
PRS 005 T 17 E  Page 27 of 45 
Strictly Confidential. Â© 2004 -2014, PRA  Health Sciences. All rights reserved.  
The following demographic data  and baseline characteristics  will be summari zed in the ITT and PP 
Populations : 
ï‚· Age at Screening  
ï‚· Age group ( â‰¥16 to â‰¤25 years, >25 to â‰¤35 years, >35 to â‰¤50 years)  at Screening  
ï‚· Highest education level 
ï‚· Ethnicity  
ï‚· Race  
ï‚· Height  
ï‚· Weight at Baseline  
ï‚· BMI at Baseline  
ï‚· BMI categories (< 30kg /m2, â‰¥30kg/m2) at Baseline  
If subjects record more than one race, then for the summary  table , these subjects will be included in the 
Other Race group . BMI will be derived programmatically from the height and weight collected.  
The subjectâ€™s previous contraceptive method used will be summarized in terms of the number and 
percentage of switche rs, starters and true new users in the ITT Population.  Note: subjects who are true 
new users are a subset of the starters.  
The following information will be summarized for gynecological history in the ITT Population:  
ï‚· Gravidity and parity status  
ï‚· Menstrual c ycle length for starters  
ï‚· Dysmenorrhea  
ï‚· Previous contraceptive method used  
ï‚· History of pregnancy during accurate hormonal contraceptive use  
Smoking status , including the following information for current smokers  will be presented in the ITT 
Population :  
ï‚· The number of days per week where the subject smokes  
ï‚· The number of tobacco products per day that the subject smokes  
All demographic data , baseline characteristics , gynecological history, contraceptive use and smoking status  
will be listed  in the ITT Population . In the demography listing, if a subject has more than one race recorded, 
then all races selected will be listed for that subject.  
Medical history will be summarized in the ITT. Medical history will be classified into a standardized 
terminology using the Medical Dictionary for Regulatory Activities (MedDRA) system organ classifications 
and preferred terms. Version 20.0 of MedDRA will be used as coding dictionary.  
Surgical history will not be summarized.  
All medical and surgical history recorded will be li sted in the ITT Population . 
9.5 Efficacy Analyses  
9.5.1  Primary Variable  
The primary variable  will be  summarized using  the Pearl Index in the ITT population aged 16 to 35 years  
inclusive at Screening with at-risk cycles.  Subjects in this age group will not be censor ed on their 36th 
Statis tical Analysis Plan  
Final  
Effective Date: 11-Dec-2018/Version 3.0 
Sponsor: Estetra  
Protocol no: MIT -Es0001 -C302  
PRS 005 T 17 E  Page 28 of 45 
Strictly Confidential. Â© 2004 -2014, PRA  Health Sciences. All rights reserved.  
birthday for the pregnancy assessment. The Pearl Index will be presented with corresponding 95% CIs. No 
formal statistical analyses will be conducted for the primary variable.  
The Pearl Index, defined as the number of pregnancies per 100 w omen -years of treatment, will be 
calculated as  
Pearl  Index = 1300  x number  of onâˆ’treatment  pregnancies
number  of women âˆ’28 day equivalent  cycles  of treatment 
Only at-risk cycles will be included in the denominator of the Pearl Index calculation. At-risk cycles will be 
defined as cycles in which the following criteria are met:  
1. No other methods of birth control (including condoms and emergency contraception)  are used by 
[CONTACT_815878]  
2. The subject confirmed that sexual intercour se occurred during the cycle in the subject diary  
Note that if conception occurs in a cycle, then that cycle will be included as an at-risk cycle in the 
denominator even if other methods of birth control were used during that cycle or the subject did not c onfirm 
that they had had sexual intercourse. Cycles after the cycle of conception will  not be included as at-risk 
cycles and will  be excluded from the denominator.  
The number of women -28 day equivalent cycles of treatment is the sum of the number of at-risk cycles 
across all subjects.  The total number of at-risk cycles will be presented in the table.   
All on -treatment pregnancies will be included in the numerator for the Pearl Index (see Section 5.9.1  for 
definition of on -treatm ent pregnancies).  
For calculation purposes a cycle will be defined as per Section 5.1.1 .  
The 95% CI for Pearl Indices will be calculated using a Poisson distribution.  The confidence interval  limits  
are calculated by [CONTACT_12801] s: 
ğ¶ğ¼ğ¿ğ‘‚ğ‘Šğ¸ğ‘… =1300 Ã—1
2ğœ’0.025 ; 2ğ‘¥2
ğ‘¡â„ğ‘’ ğ‘›ğ‘¢ğ‘šğ‘ğ‘’ğ‘Ÿ  ğ‘œğ‘“ ğ‘¤ğ‘œğ‘šğ‘’ğ‘› âˆ’28 ğ‘‘ğ‘ğ‘¦  ğ‘’ğ‘ğ‘¢ğ‘–ğ‘£ğ‘ğ‘™ğ‘’ğ‘›ğ‘¡  ğ‘ğ‘¦ğ‘ğ‘™ğ‘’ğ‘   ğ‘œğ‘“ ğ‘¡ğ‘Ÿğ‘’ğ‘ğ‘¡ğ‘šğ‘’ğ‘›ğ‘¡  
 
ğ¶ğ¼ğ‘ˆğ‘ƒğ‘ƒğ¸ğ‘… =1300 Ã—1
2ğœ’0.975 ; 2(ğ‘¥+1)2 
ğ‘¡â„ğ‘’ ğ‘›ğ‘¢ğ‘šğ‘ğ‘’ğ‘Ÿ  ğ‘œğ‘“ ğ‘¤ğ‘œğ‘šğ‘’ğ‘› âˆ’28 ğ‘‘ğ‘ğ‘¦  ğ‘’ğ‘ğ‘¢ğ‘–ğ‘£ğ‘ğ‘™ğ‘’ğ‘›ğ‘¡  ğ‘ğ‘¦ğ‘ğ‘™ğ‘’ğ‘   ğ‘œğ‘“ ğ‘¡ğ‘Ÿğ‘’ğ‘ğ‘¡ğ‘šğ‘’ğ‘›ğ‘¡ 
where x is the number of on -treatment pregnancies.  
The Pearl Index and corresponding 95% CIs will be presented by [CONTACT_815891] 4.[ADDRESS_1129801] diary data , pregnancy information and at-risk cycles for each 
analysis will be listed.  
9.5.2  Secondary Variables  
[IP_ADDRESS]  Pearl Index  
The Pearl Index and corresponding 95% CIs will be presented for all subjects in the ITT Population (see 
Section 9.5.1  for details)  including only at-risk cycles in the denominator . At-risk cycles will be defined as 
cycles in which no other methods of birth control (including condoms and emergency contraception)  are 
used by [CONTACT_815878] , and the subject confirmed that sexual intercourse 
occurred during the cycle in the subject diary.  The number of on -treatment pregnancies and at-risk cycles 
will be presented.  
Statis tical Analysis Plan  
Final  
Effective Date: 11-Dec-2018/Version 3.0 
Sponsor: Estetra  
Protocol no: MIT -Es0001 -C302  
PRS 005 T 17 E  Page 29 of 45 
Strictly Confidential. Â© 2004 -2014, PRA  Health Sciences. All rights reserved.  
The Pearl Index and corresponding 95% CIs will be  presented for subjects aged 16 to 35 years  and for all 
subjects in the ITT Population including all cycles in the denomin ator with the exception of c ycles after the 
cycle of conception in the case of pregnancy .  
The Pearl Index and corresponding 95% CIs w ill also be presented for subjects aged 16 to 35 years  and 
for all subjects in the ITT Population employing a modified at-risk definition. With this definition, at-risk 
cycles will be defined as cycles in which no other methods of birth control (including condoms and 
emergency contraception)  are used  by [CONTACT_815892] .  
[IP_ADDRESS]  Method Failure Pearl Index  
The method failure Pearl Index is calculated using the same method as the Pe arl Index (see Section 9.5.1  
for details), but includes only those pregnancies that were classified as method failure (see Section 5.9.4  
for details). Pregnancies due to user failure will be exclude d from the numerator.  
The method failure Pearl Index and corresponding 95% CIs will be presented for subjects aged 16 to 35 
years  at Screening in the ITT Population and for all subjects in the ITT Population  including only at-risk 
cycles in the denominator . The number of on -treatment pregnancies and at-risk cycles will be presented . 
This will be derived in 4 ways:  
ï‚· Including all at-risk cycles in the denominator where at-risk cycles will be defined as cycles in which 
no other methods of birth control (includ ing condoms and emergency contraception)  are used by 
[CONTACT_815893].  
ï‚· Including all at-risk cycles in the denominator  employing a  modified at-risk definition. With this 
definition, at-risk cycles will be defined as cycles in which no other methods of birth control 
(including condoms and emergency contraception)  are used  by [CONTACT_815894].   
ï‚· Including only at-risk cycles in the denominator where at-risk cycles will be defined as cycles in 
which no other methods of birth control (including condoms and emergency contraception)  are 
used by [CONTACT_423] a s confirmed in the subject diary and the subject confirmed that sexual 
intercourse occurred during the cycle in the subject diary where the subject was compliant with the 
dosing rules  3 to 8 in Section 5.1.1 .  
ï‚· Including only modified at-risk cycles in the denominator where at-risk cycles will be defined as 
cycles in which no other methods of birth control (including condoms and emergency contraception)  
are used by [CONTACT_815895] w as compliant with the 
dosing rules  3 to 8  in Section 5.1.1  while cycles with and without confirmed intercourse are being  
included  in the denominator.   
[IP_ADDRESS]  Life-Table Rates  
In addition, the cumulative pregnancy rate, as determined b y life -table methods, together with the 
corresponding 95% CIs will be presented for all pregnancies and for all method failure pregnancies in the 
ITT population for all subjects  and for subjectâ€™s aged 16 to 35 years  inclusive at Screening.  
Life-table analy ses will provide one -year life -table pregnancy rates for each efficacy endpoint (i.e. for all 
pregnancies as used in the Pearl Index and for all method failure pregnancies as used in the method failure 
Pearl Index). The life -table analysis will evaluate th e cumulative probability of pregnancy by [CONTACT_815896] -treatment event of pregnancy. Subjects who did not have an on -treatment event 
of pregnancy will be censored on the cycle prior to the cycle in  which they discontinued from the study. The 
rate of pregnancy and 95% CIs will be calculated based on Kaplan -Meier estimates for each cycle . 
Additionally, the estimated surviv al function agai nst time (cycle) will be provided.  
Statis tical Analysis Plan  
Final  
Effective Date: 11-Dec-2018/Version 3.0 
Sponsor: Estetra  
Protocol no: MIT -Es0001 -C302  
PRS 005 T 17 E  Page 30 of 45 
Strictly Confidential. Â© [ADDRESS_1129802] diary.  A cycle analysis and an analysis by 
[CONTACT_815897] (see Section 5.1.2  for details ). Derived da ta for bleeding and spotting will be listed in 
the ITT Population.  
[IP_ADDRESS]  Cycle Analysis   
The cycle analysis will be performed following two approaches: a classical (for details see Section [IP_ADDRESS] ) 
and a modified cycle analysis (fo r details see Section [IP_ADDRESS] ).  
The classical analysis will be performed in the ITT and PP Population. This analysis will also be repeated 
for the following populations:  
ï‚· The PP analysis excluding cycles where there is at leas t 1 day where an active pi[INVESTIGATOR_815858]  
ï‚· The ITT analysis including only cycles where 1 active pi[INVESTIGATOR_815858]  
ï‚· The ITT analysis including only cycles where [ADDRESS_1129803] and cycle along with reasons for exclusion of the cycle from the PP 
Population analysis  and the number of missed p ills. 
The following information will be summarized for bleeding and spotting for the cycle analysis : 
ï‚· Number and percentage of subjects with unscheduled bleeding and/or spotting epi[INVESTIGATOR_815859] (classical analysis  + modified cycle analysis ) 
ï‚· Number a nd percentage of subjects with unscheduled bleeding  only epi[INVESTIGATOR_815860]  
(classical analysis  + modified cycle analysis )  
ï‚· Number and percentage of subjects with unscheduled spotting  only epi[INVESTIGATOR_815860]  
(classical analysis  + modified cycle a nalysis )  
ï‚· Number and percentage of subjects with absence of  a scheduled bleeding and/or spotting  epi[INVESTIGATOR_815861]  (classical analysis  + modified cycle analysis ) 
ï‚· Number and percentage of subjects with early withdrawal bleeding  and/or spotting  for each  cycle   
ï‚· Number and percentage of subjects with continued withdrawal bleeding  and/or s potting  for each 
cycle   
ï‚· Number and percentage of subjects with absence of any bleeding and/or spotting for each cycle   
ï‚· Descriptive statistics (e.g., mean, SD, median, mini mum, and maximum) for the number of days of 
bleeding and/or spotting, bleeding only, and spotting only within a cycle for  (classical and modified 
cycle analysis) : 
o Total Days (Unscheduled + Scheduled)  
o Unscheduled Days  
o Scheduled Days  
Statis tical Analysis Plan  
Final  
Effective Date: 11-Dec-2018/Version 3.0 
Sponsor: Estetra  
Protocol no: MIT -Es0001 -C302  
PRS 005 T 17 E  Page 31 of 45 
Strictly Confidential. Â© 2004 -2014, PRA  Health Sciences. All rights reserved.  
ï‚· Cumulative number and pe rcentage of subjects with absence of withdrawal bleeding  and/or 
spotting  in the ITT Population only  (classical analysis)  
o The number of subjects who have no withdrawal bleeding and/or spotting  that started in at 
least [ADDRESS_1129804] 13 evaluable cycles, 
respectively, for the specified pop ulation  
Note that the denominator for the percentages listed above will be the number of subjects with an evaluable 
cycle unless otherwise specified . 
The percentage of subjects with bleeding, the percentage of subjects with spotting and the percentage of 
subjects with absence of bleeding and/or spotting for each day will be presented in a bar chart over time 
for the ITT , PP Populations  and Populations based on active pi[INVESTIGATOR_10685] . The plot will start on Day [ADDRESS_1129805] the true ble eding pattern.  Day will be 
the day from the diary data i.e. pi[INVESTIGATOR_815862] (examples: Day 4 = Cycle 1 Day 4 or Day 118 = Cycle 5 Day 
6). The denominator will be the number of subjects with an evaluable cycle for the specified population on 
that day.  
The descriptive statistics (e.g., mean, SD, median, minimum, and maximum) for the number of unscheduled 
bleeding and/or spotting  days , bleeding  days , and spotting days within a cycle will also be summarized in 
subjects who experienced  an unscheduled bleeding and/or spotting epi[INVESTIGATOR_815828]. This will be 
presented for the classical and modified analysis in the ITT and PP Populations. Additionally, unscheduled 
bleeding and spotting and the absence of scheduled bleeding will be summarized for all subgro ups 
specified in Section 4.[ADDRESS_1129806] 1 missed active pi[INVESTIGATOR_815863] I TT 
Population . 
The number and percentage of subjects with a scheduled bleeding epi[INVESTIGATOR_815864] (i.e. Day 25, 26, 27, 28 and Day 1, 2 and 3 of the next cycle 
in the diary) will be summarized  by [CONTACT_51199]. If there is more than one scheduled bleeding epi[INVESTIGATOR_1865], then the 
only the earliest start date of the  scheduled bleeding epi[INVESTIGATOR_1865] s starting within the cycle  will be counted . This 
will be presented for the classical and modified analysis in the ITT P opulation.  
[IP_ADDRESS]  Reference Period Analysis  
All RP analysis will be performed in the ITT Population only . The following information will be summarized 
for bleeding and spotting for the RP analysis : 
ï‚· Descriptive statistics (e.g., mean, SD, median, minimum, and maxi mum) for the number of days of 
bleeding and/or spotting, bleeding only, and spotting only within a RP.  
ï‚· Descriptive statistics for the number of bleeding and/or spotting epi[INVESTIGATOR_815865]  
ï‚· Descriptive statistics for the mean duration of the bleeding and/o r spotting epi[INVESTIGATOR_815865]  
ï‚· Descriptive statistics for the number of bleeding and/or spotting free epi[INVESTIGATOR_815865]  
ï‚· Descriptive statistics for the mean duration of the bleeding and/or spotting free epi[INVESTIGATOR_815866] t he percentages listed above will be the number of subjects with an evaluable 
RP.  
The number of subjects with evaluable reference periods for each population will be summarized by 
[CONTACT_815898].  The inclusion of reference periods in ITT Population will be listed by [CONTACT_815899].  
Statis tical Analysis Plan  
Final  
Effective Date: 11-Dec-2018/Version 3.0 
Sponsor: Estetra  
Protocol no: MIT -Es0001 -C302  
PRS 005 T 17 E  Page 32 of 45 
Strictly Confidential. Â© 2004 -2014, PRA  Health Sciences. All rights reserved.  
9.6 Safety Analyses  
9.6.1  Adverse Events  
TEAEs will be classified into a standardized terminology using the MedDRA system organ classifications 
and preferred terms. Version  20.0 of MedDRA will be used as coding dictionary. The incidence of TEAEs 
will be summarized for the Safety Population.  
A summary of TEAEs  including the number of events reported , the annual rate and the number and 
percentage  of subjects reporting th e following will be presented:  
ï‚· Any TEAE  
ï‚· Any TEAE leading to death  
ï‚· Any treatment -emergent SAE  
ï‚· Any TEAE leading to premature discontinu ation from the study  
ï‚· Any SAE related to study medication  
TEAE s are defined in Section 5.11. The annual rate will be derived as the number of events divided by [CONTACT_815900].  
A breakdown of the number and percentage of subjects reporting each TEAE  with the corresponding 
number of events , categorized by [CONTACT_815901], will be presented. Note that subjects are only counted once within each body system or preferred 
term but subjects with multiple events of a specific type will be counted once for each occurrence in the 
number of events column . 
A further tabulation of these data, categorized by [CONTACT_8792], will be presented. Subjects 
with multiple events within a particular body system or preferred term will be counted under the cate gory of 
their most drug -related event within that body system or preferred term  in column for the number of subjects . 
In the column for the number of events, multiple events of a specific type and relationship will be counted 
once for each occurrence.  Relationship to study drug is categorized as not related ( not related  and unlikely  
on the CRF) and related ( possible, probable and highly probable  on the CRF ). This will be repeated for 
TEAEs leading to premature discontinuation from the study.  
TEAEs  will also be presented  by [CONTACT_926] . For each system organ class and preferred term, subjects are 
included only once, at the maximum severity . In the column for the number of events, multiple events of a 
specific type and severity  will be counted once for each occur rence.  
All adverse events (including non -treatment -emergent events) recorded on the CRF will be listed.  The 
following listings will be generated  in the Screen ed Population : 
ï‚· All AEs  
ï‚· AEs leading to premature discontinuation from the study  
9.6.[ADDRESS_1129807] 
drug-related event within t hat body system or preferred term in column for the number of subjects. In the 
column for the number of events, multiple events of a specific type and relationship will be counted once 
for each occurrence. Relationship to study drug is categorized as  not related  (not related  and unlikely  on 
the CRF) and related  (possible, probable and highly probable on the CRF ).  
The following listings will be generated including non -treatment emergent events  in the Screened  
Population : 
Statis tical Analysis Plan  
Final  
Effective Date: 11-Dec-2018/Version 3.0 
Sponsor: Estetra  
Protocol no: MIT -Es0001 -C302  
PRS 005 T 17 E  Page 33 of 45 
Strictly Confidential. Â© 2004 -2014, PRA  Health Sciences. All rights reserved.  
ï‚· All SAEs  
ï‚· All AEs leading to death  
ï‚· All SAEs related to treatment (includes SAEs where the relationship to study drug is possible, 
probable and highly probable)  
9.6.3  Laboratory Data  
Central laboratory data will be used for the tables and listings. The s cheduled laboratory assessments will 
be included in the tables  where data are available . If a specific parameter is missing at the scheduled 
assessment and there is an unscheduled assessment collected at the same visit where this parameter is 
not missing, then the value at the unscheduled assessment w ill be used in the table. Otherwise 
unscheduled assessments will not be included in the tables.  Note that  unscheduled pregnancy tests will be 
used in the assessment of pregnancies for the primary endpoint . The parameters listed in Table 4 will be 
summari zed. Separate outputs will be provided for hematology, serum chemistry and lipid profile.  
Table 4: Laboratory Parameters  
Hematology  
Hemoglobin  Mean cell volume  
Hematocrit  White blood cell & Differential  
Red blood cell count  Platelet count  
Serum Chemistry  
Albumin  Total protein  
Alanine aminotransferase (ALAT)  Serum creatinine  
Aspartate aminotransferase (ASAT ) Sodium  
Blood urea nitrogen  Potassium  
Gamma glutamyl transferase (GGT)  Calcium  
Glucose  Chloride  
Glycated hemoglobin  Bicarbonate  
Lactate dehydrogenase  (LDH) 1 and LDH 2   Phosphorus  
Total bilirubin  Choriogonadotropin Beta (Serum Pregnancy Test)  
Estimated Glomerular Filtration Rate (eGFR)   
Lipid Profile  
Total cholesterol  Triglycerides  
High density lipoprotein cholesterol  Low density lipoprotein cholesterol  
 
For continuous clinical laboratory analytes, the absolute value and change from baseline will be 
summarized by [CONTACT_815902] e Safety Population.  
Shifts to values outside of the normal range will be presented by [CONTACT_815903]. The denominators for calculating the 
percentages will be the nu mber of subjects in the Safety Population with both the Baseline value and the 
value at the specified visit recorded . 
If the value is below the lower limit of quantification, then half the lower limit of quantification will be used in 
the summary tables to  calculate the descriptive statistics. If the value is above the upper limit of 
quantification, then the upper limit of quantification will be used in the summary tables to calculate the 
descriptive statistics . In the listings, v alues will be listed as col lected without the imputation applied.  
All clinical laboratory values, abnormal clinical laboratory values, and clinical significant laboratory values 
will also be provided in data listings  in the Safety Population  including data collected at any unschedu led 
assessments . 
Statis tical Analysis Plan  
Final  
Effective Date: 11-Dec-2018/Version 3.0 
Sponsor: Estetra  
Protocol no: MIT -Es0001 -C302  
PRS 005 T 17 E  Page 34 of 45 
Strictly Confidential. Â© [ADDRESS_1129808] results will be listed.  
9.6.4  Vital Signs  
Unscheduled vital signs assessments will be excluded from the tables.  
Vital sign measurements (systolic blood pressure, diastolic blood pressure and heart rate) for the Safet y 
Population will be summarized using descriptive statistics by [CONTACT_765]. The change from Baseline will also be 
summarized in the same manner.  
Weight and BMI measurements for the Safety Population will be summarized using descriptive statistics by 
[CONTACT_765]. The change from Baseline will also be summarized in the same manner.  BMI will be derived 
programmatically from the height and weight collected.  
All vital signs, weight and BMI measurements will be listed  in the Safety Population  including data collected 
at any  unscheduled assessments . 
9.6.5  Physical  and Gynecological  Examinations  
Physical and gynecological examination assessments  will be summarized for the Safety population by [CONTACT_765]. 
For each body system and assessment category, the number and percentage of subjects will be  presented. 
The denominators for calculating the percentages will be based on the number of  subjects evaluated for a 
particular body system.  Unscheduled physical examinations will not be summarized.  
All physical  and gynecological  examination data wi ll be listed  in the Safety Population . 
9.7 Other Secondary Endpoints  (Excluding PK)  
9.7.[ADDRESS_1129809], impaired concentration, behaviour change, 
arousal and control will be summarized descripti vely by [CONTACT_815904] . The phases are menstrual (most 
recent flow), premenstrual (four days before) and intermenstrual (remainder of cycle).   
All quality of life data will be listed  in the ITT Population . 
9.7.[ADDRESS_1129810] dose of study medication to return of menses will be summarized using descriptive 
statistics in the Safety Population.  
The following  will be summarized using descriptive sta tistics  for subjects in the Safety Population who 
discontinue d study medication due to a pregnancy wish  who selected the corresponding fertility information:  
ï‚· Time from last dose of study medication to estimated date of conception  
ï‚· Time from last dose of st udy medication to new contraceptive method  
Statis tical Analysis Plan  
Final  
Effective Date: 11-Dec-2018/Version 3.0 
Sponsor: Estetra  
Protocol no: MIT -Es0001 -C302  
PRS 005 T 17 E  Page 35 of 45 
Strictly Confidential. Â© 2004 -2014, PRA  Health Sciences. All rights reserved.  
The estimated date of conception is derived as the expected date of pregnancy term â€“ 38 weeks  (266 
days) .  
Data for follow -up evaluations will be listed for subjects in the Safety Population who discontinued study  
medication due to a pregnancy wish.  
9.8 Population Pharmacokinetics Analysis  
9.8.1  Data Included in Analysis  
Data from study MIT-Es0001 -C302  are very sparse (two samples at each of two visits per subject,  and 
collected relatively close together). These data alone will likely not support identification of many of the 
model parameters. To insure identifiability of parameters required to meet the objectives, rich data from 
study  Es0001 -C101  will be included in the data set. Additional data from study MIT -Es0001 -C103 m ay be 
included in the population PK analysis if relevant parameters are not identifiable with data from only MIT-
Es0001 -C302  and Es0001 -C101 .  
9.8.[ADDRESS_1129811] of various individual characteristics/covariates ( e.g., body w eight, 
race, smoking,  and fed vs fast ed status) on the pharmacokinetics (PK) of 15 mg Estetrol (E4)/3 mg 
Drospi[INVESTIGATOR_187306] (DRSP).  As data permit, PK parameters will include, but are not limited to:  
ï‚· Primary parameters (i.e. model parameters):  
o Apparent clearance  (CL/F).  
o Central volume of distribution (V/F).  
o Lag time of Absorption ( Tlag), if necessary.  
o Relative bioavailability for fed vs fasted state . 
ï‚· Secondary parameters (i.e. derived parameters ): 
o Maximum concentration (Cmax).  
o Time to Cmax (Tmax).  
o Extent of expos ure for the dosing interval (AUC tau) at steady state.  
o Terminal half -life (t Â½). 
o Predicted trough drug concentration (Ctrough)  at steady state . 
o Distribution half -life (t Â½) (if applicable) . 
9.8.[ADDRESS_1129812] recent rep orted value (last value carried forward) if any are 
reported for that subject. If no value is available, missing covariates will be imputed as the median of all 
other subjects  within the study . 
Patients will record time of the most recent dose prior to sam ple collection. This dose will be assumed to 
be at steady state, with a [ADDRESS_1129813].  
9.8.4  Prespecified Hypotheses  
Pre-specified hypothes es will be tested before any hypotheses that are based on diagnostic plots. Formal 
conclusions will be drawn only from these prespecified hypotheses. Results of other hypotheses (e.g., those 
based on diagnostic plots) will be considered exploratory  and wil l not lead to conclusions .  
1. Effect of body weight on volume of distribution of E4.  
2. Effect of body weight on clearance of E4  
3. Effect of race on clearance for E4.  
4. Effect of smoking status on clearance for E4.  
Statis tical Analysis Plan  
Final  
Effective Date: 11-Dec-2018/Version 3.0 
Sponsor: Estetra  
Protocol no: MIT -Es0001 -C302  
PRS 005 T 17 E  Page 36 of 45 
Strictly Confidential. Â© [ADDRESS_1129814] of fed vs fasted state on rate (e.g. Ka) or  extent (e.g., F) of absorption for E4.  
6. Effect of body weight on volume of distribution of DRSP.  
7. Effect of body weight on clearance of DRSP  
8. Effect of race on clearance of DRSP.  
9. Effect of smoking status on clearance of DRSP.  
10. Effect of fed vs fasted state o n rate (e.g. Ka) or extent (e.g., F) of absorption for DRSP . 
 
9.8.5  Study MIT -Es0001 -C302  
A Multicenter, Open -label, Single -Arm Study to Evaluate the Contraceptive Efficacy and Safety of a 
Combined Oral Contraceptive Containing 15 mg Estetrol and 3 mg Drospi[INVESTIGATOR_815867]. 
 
Two PK samples will be taken from the subjects in the Population PK Substudy at Visits 3 and 4. All subjects 
included in the Substudy will provide a sample for PK analysis at the time they check into the site (PK 
sampling 1). An additional blood samp le (PK sampling 2) will be collected approximately two hours after 
the first sample.  
 
The following timings will be recorded by [CONTACT_815905]:  
- The exact times of the last study medication dosing and the PK samplings 1 and 2.  
Depending on  the time scheduled for the study site visit (Visit 3 & 4), subjects were instructed on 
when they need to take their medication â€“ either as usually done at home or on site. One blood 
sample will be taken before dosing and the second blood sample will be ta ken within [ADDRESS_1129815] of food on the bioavailability of 15 mg Estetrol/[ADDRESS_1129816] 10 hours prior 
to each dose. All subjects received the following 2 treatments:  
ï‚· Treatment A (Reference): a single 15 mg E4 /3 mg DRSP tablet without food (fasted).  
ï‚· Treatment B (Test): a single 15 mg E4/3 mg DRSP tablet with food (fed).  
All subjects received both Treatment A and Treatment B either at the first treatment period (Period 1) or the 
second treatment period (Period 2 ). Approximately half of the subjects were randomized to receive either 
Treatment A followed by [CONTACT_75891] B (Sequence AB), or Treatment B followed by [CONTACT_75891] A (Sequence 
BA) as described in Table 5. 
PK Sampling: Blood samples were collected prior to each  dose and at 10, 20, [ADDRESS_1129817] -dose for pharmacokinetic (PK) 
analysis.  
Table 5.  Treatment Sequences  
Statis tical Analysis Plan  
Final  
Effective Date: 11-Dec-2018/Version 3.0 
Sponsor: Estetra  
Protocol no: MIT -Es0001 -C302  
PRS 005 T 17 E  Page 37 of 45 
Strictly Confidential. Â© 2004 -2014, PRA  Health Sciences. All rights reserved.  
Sequence  Period 1  Period 2  
AB  Treatment A: 1 tablet 15 m g 
E4/3 mg DRSP in fasted conditions  Treatment B: 1 tablet 15 mg 
E4/3 mg DRSP in fed conditions  
BA Treatment B: 1 tablet 15 mg 
E4/3 mg DRSP in fed conditions  Treatment A: 1 tablet 15 mg 
E4/[ADDRESS_1129818] Modelling Of Estetrol (E4) In 
Combination With Drospi[INVESTIGATOR_187306] (DRSP) After Single And Multiple Dosing In  Healthy Women.  
 
MIT Es0001 -C103 was a randomized, double -blind, placebo -controlled, parallel, single and multiple oral 
dose study to investigate the PK, safety and tolerability of therapeutic and supratherapeutic single and 
multiple doses of E4 in combina tion with DRSP in healthy female subjects. A total of [ADDRESS_1129819] 14 days, multiple doses during 14 
consec utive days from Days 15 to 28.  
 The following treatments  in Table 6 were  administered:  
Table 6.  MIT-ES0001 -C103 Treatments  
 Dose Level E4 (mg)  Dose Level DRSP 
(mg)  Dosage  
Group 1  15  3 Therapeutic E4/DRSP 
dose level  
Group 2  30 6 2 times therapeutic 
E4/DRSP dose l evel 
Group 3  60 12 4 times therapeutic 
E4/DRSP dose level  
E4 = Estetrol ; DRSP = Drospi[INVESTIGATOR_187306].  
Drug administration on Days [ADDRESS_1129820] to meals; however, subjects will be 
fasted before all clinical laboratory assessments.  
PK sampling:  Samples for pharmacokinetic analysis were collected at the following times:  
On Day 1 and Day 28: at pre -dose and at [ADDRESS_1129821] -dose.  
On Days 17, 19, 21, 23, 25 and 27: at pre -dose.  
9.8.8  Data management  
A NONMEM data set will be created from source data files provided by [CONTACT_815906] -Es0001 -C302 
and by [CONTACT_815907]0001 -C101 and (if used) MIT-Es0001 -C103  and will undergo quality control (QC) 
review according to SOPs at the time of the finalization of the analysis plan.  
The data manager will create one or more code files to automate the process of formatting th e source 
dataset into the popPK dataset. No manual editing of the data will be done. The code file for the creation 
of the popPK datasets will be in R version 3.3.1 or later (R Foundation for Statistical Computing, Vienna, 
Austria).  
Statis tical Analysis Plan  
Final  
Effective Date: 11-Dec-2018/Version 3.0 
Sponsor: Estetra  
Protocol no: MIT -Es0001 -C302  
PRS 005 T 17 E  Page 38 of 45 
Strictly Confidential. Â© 2004 -2014, PRA  Health Sciences. All rights reserved.  
A popPK data set can b e very large. QC of the final NONMEM dataset will include manual comparison of 
a subset of the records to the source data (Sponsor or PRA provided dat asets) as well as diagnostics on 
the entire dataset to identify errors. Diagnostics will also be performed  to ensure that the dataset complies 
with the formatting standards for NONMEM. The QC may include review of the code used to generate the 
dataset, as appropriate. This QC will be done by [CONTACT_815908]. Any discrepancies 
will be addr essed. Revised datasets will undergo quality control to confirm that the expected changes (e.g., 
deleted data records) are correct. The scope of the QC will be dependent on the nature and complexity of 
the study, as well as the source data. Any unique or c omplicated formatting issues associated with the 
dataset will be flagged by [CONTACT_815909].  
9.8.9  Data Deletion  
[IP_ADDRESS]  Missing Data  
Incomplete data (e.g., missing dosing times) is a frequent occurrence in population analysis data sets. 
Typi[INVESTIGATOR_183812], data with a missing or clearly erroneous dose time will be imputed per protocol or deleted  as 
appropriate .  
[IP_ADDRESS]  Erroneous Data  
Data in the Sponsor data set will occasionally be found to be inconsistent with the known pharmacokinetics 
of the drug or study procedures. These may be a result of recording errors in the database (e.g., dose 
administered prior to study start or after study completion) or unrealistic pharmacokinetic considerations. 
These data may be deleted if they cannot be corrected based on dat a review and site queries.  
[IP_ADDRESS]  Outliers  
Outliers will be distinguished from erroneous data as being unusual but not inconsistent with the known 
pharmacokinetics of the drug. Outlier data may include entire subjects, entire subject visits, or individual 
obser vations. Outliers will be deleted only after careful examination of possible causes.  
9.8.10  PopPK Model Development  
Population pharmacokinetic model development will be performed in compliance with SOPs at the time of 
the finalization of the analysis plan.  
[IP_ADDRESS]  Data  Set Creation  
Prior to initiation of analysis, NONMEM and other population PK software require specifically formatted data 
sets. Creation of these data sets is addressed Section 9.8.6 .  
[IP_ADDRESS]  Handling Data below the Limit of Quantifi cation (BLQ)  
BLQ data will be handled according to the â€œM3â€ methodology ( Beal, 2001 ). 
[IP_ADDRESS]  Model Development Procedures  
A Bayesian analysis will be used to fit concentration -time data. Model features (number of compartments, 
lag times, covariate effects) will be included based on goodness of fit statistics (e.g., log -likelihood) and 
diagnostic plots. Th ese pharmacokinetic models will be evaluated and used to derive individual post hoc 
pharmacokinetic parameters for E4 and DRSP desc ribed in Objectives ( 9.8.2 ).  
Initial estimates of PK parameters (e.g., CL/F, V/F, Tlag) will be determined using exploratory 
compartmental analyses or previous PK analysis. These estimates will be employed to build an appropri ate 
population PK model. The impact of individual characteristics on the PK parameters will be explored and 
included in the population model if significant.  
Statis tical Analysis Plan  
Final  
Effective Date: 11-Dec-2018/Version 3.0 
Sponsor: Estetra  
Protocol no: MIT -Es0001 -C302  
PRS 005 T 17 E  Page 39 of 45 
Strictly Confidential. Â© 2004 -2014, PRA  Health Sciences. All rights reserved.  
9.8.11  PopPK Model Evaluation  
A traditional approach  to model selection will be used. In this approach, an initial simple model is run. 
Additional features are sequentially added to this model (e.g., compartments, lag times, variance terms, 
covariates), testing each addition for statistical significance, improvement of diagnostic graphics and/or 
biological p lausibility. Model features (e.g., lag times, compartments) will be added or removed based on 
evaluation of diagnostic plots, consideration of biological plausibility, and statistical tests. The goodness -
of-fit between hierarchical models is measured by [CONTACT_3433] e difference in the objective function value (OFV) 
produced by [CONTACT_52630]. The difference in OFV between two hierarchical or nested models is approximately 
Ï‡2 distributed, with n degrees of freedom. As such, the OFV is used to obtain the significance level for  the 
difference between two nested models. The criteria for forward addition will be p<0.[ADDRESS_1129822] elimination will be p<0.001. Covariate analyses will be performed separately for the PK of E4 and 
DRSP.  
Assessment of model adequacy a nd decisions about increasing model complexity will be driven by [CONTACT_815910] -of-fit criteria, including:  
1. Visual inspection of diagnostic plots ( e.g.,observed vs. predicted concentration, residual/weighted 
residual versus predicted c oncentration or time , and histograms of individual random effects).  
2. Successful convergence of the minimization routine with at least 2 significant digits in parameter 
estimates. Successful minimization and covariance steps will be desired, but not requ ired. 
3. Plausibility of parameter estimates.  
4. Precision of parameter estimates, if available.  
5. Correlation between model parameter estimation errors < 0.95.  
6. Likelihood ratio test.  
7. Asymptotic and or Bootstrap estimate of confidence interval f or parameter estimates . 
Covariates to be considered during population pharmacokinetic model building include, but are not limited 
to, variables such a s body weight,  race, smoking, and fed vs fasted status . Pre -specified hypo theses will 
be examined first, f ollowed by [CONTACT_815911]. If applicable, this will be followed 
by [CONTACT_815912] ( SCM user guide ). 
[IP_ADDRESS]  Visual Predictive Check  
In order to verify that the final model adequately predic ts both the central tendency and the variability of the 
observed data, a visual predictive check (VPC) stratified by [CONTACT_8497], race, smoking status , and fed/fasted 
status will be performed. VPC plots will be made for two or three strata for weight and each stratum for the 
categorical covariates. For the VPC, simulations will be performed using the final model and final model 
parameters. The original data set will be used as a template for simulation input. Simulations will be 
performed to generate approximate ly 1,000 simulated observations at each time point; if 1,000 simulated 
observations are not feasible based on the model run times, a reduced number of simulated observations 
will be used. A graphical comparison will be made between the observed data and th e model predicted 
median and 95% prediction interval over time. Additional VPC plots may be generated to include confidence 
intervals for the median and prediction intervals of the simulated data. VPC will be conducted in PsN and 
the result will be summari zed using Xpose ( Jonsson and Karlsson, 1999 ). 
9.8.12  Reporting  
A submission ready report will be developed, as described below.  
[IP_ADDRESS]  Report Structure  
The popPK report will comprise the following sections:  
1. Summary  
Statis tical Analysis Plan  
Final  
Effective Date: 11-Dec-2018/Version 3.0 
Sponsor: Estetra  
Protocol no: MIT -Es0001 -C302  
PRS 005 T 17 E  Page 40 of 45 
Strictly Confidential. Â© [ADDRESS_1129823] of assumptions, with supporting data, as applicable. Assumptions will not be formally 
tested.  
4. Materials and Methods  
a. Data: description of data, to include (as applicable and appropriate) the number of 
individuals, number of observations, and range of sample collection times.  
b. Data analysis methods:  
i. The methods (e.g., forward addition/backward elimination) and criteria for model 
selection (li kelihood ratio test, diagnostic plots).  
5. Results  
a. PopPK results  
i. Data description: summary statistics including mean, median, and SD of 
continuous covariates, and distributions of discrete covariates.  
ii. Description of base model, including parameter estimates  and model 
qualification/diagnostic plots.  
iii. Description of final model, including parameter estimates and model 
qualification/diagnostic plots.  
6. Conclusion  
Conclusions will be based on pre -specified hypotheses only. Hypotheses generated during 
analysis (e. g., from diagnostic plots) will be considered exploratory only.  
7. Discussion  
8. Figures  
a. Figures supporting model selection decisions will be included in the report.  
b. Typi[INVESTIGATOR_815868]. Time , vs. 
Conditional  Weighted Residual s vs.  Prediction, and Observed Dependent Variable vs. 
Prediction/Individual Prediction.  
c. VPC (Visual Predictive Check).  
d. Histogram of post hoc ETAs.  
e. Observed values vs. individual predicted values.  
f. Observed values vs . population predicted values . 
9.8.13  Source Files  
The following documents will be provided as ASCII text files based on the final analysis:  
a. Source data used in the analysis (NONMEM data set).  
b. Base model control file.  
c. Base model output file.  
d. Final Model control file.  
e. Final model output  file. 
Statis tical Analysis Plan  
Final  
Effective Date: 11-Dec-2018/Version 3.0 
Sponsor: Estetra  
Protocol no: MIT -Es0001 -C302  
PRS 005 T 17 E  Page 41 of 45 
Strictly Confidential. Â© 2004 -2014, PRA  Health Sciences. All rights reserved.  
10.0 Validation  
PRA's goal is to ensure that each TFL delivery is submitted to the highest level of quality. PRAâ€™s quality 
control procedures will be documented separately in the study specific Quality Control Plan.  
11.0 References  
Beal S. L. Ways to fit a P K model with some data below the quantification limit. J Pharmacokinet 
Pharmacodyn 28(5), 481 -504 (2001).  
Gerlinger, C., Endrikat, J., van der Meulen, E. A., Dieben, T. O. & Dusterberg, B. Recommendation for 
confidence interval and sample size calculation for the Pearl Index. Eur.J.Contracept.Reprod.Health Care 
8, 87 -92 (2003).  
Jonsson E.N and Karlsson M.O. Xpose --an S-PLUS based population pharmacokinetic/  pharmacodynamic 
model building aid for NONMEM. Comput Methods Programs Biomed. Jan;58(1):51 -64 (1999) . 
Moos, R. H. The development of a menstrual distress questionnaire. Psychosom Med 30, 853 -867 (1968).  
SCM user guide http://psn.sourceforge.net/pdfdocs/scm_userguide.pdf. Accessed [ADDRESS_1129824] 2016.  
12.0 Amendment to the Statistical Analysis Plan  
12.1 Amendment 1  from SAP dated 12 December  2016 
The key changes to the SAP in amendment  1 are as follows : 
ï‚· Missing data rules moved to one section for missing data  
ï‚· The addition of analyses for the Pearl Index to look at the rate of on-treatment pregnancies  and 
on-treatment met hod failure pregnancies  where the at-risk cycles are defined as cycles in which 
no other methods of birth control are used by [CONTACT_423]  
ï‚· The addition of a n analysis for the Pearl Index to look at the rate of method failure on -treatment 
pregnancies excludi ng at-risk cycles that were not compliant according to Section 9.4.4 of the 
protocol  
ï‚· Clarification of the definition of the evaluable cycles for the bleeding analysis in the PP Population 
in cases where the post Screening biopsy was not performed during Cy cle 13  
ï‚· Addition of criteria for exclusion from the PP Population to exclude cycles within 28 days after 
prohibited mediations  
ï‚· Clarification that the Baseline value for the Menstrual Distress Questionnaire is the value 
collected at Visit 3 as the date of co llection is not collected  
ï‚· Clarification added that compliance by [CONTACT_815913] 5.1 including detail on how gaps between cycles and overlappi[INVESTIGATOR_815869] e handled  
ï‚· Clarification added that for overall compliance only pi[INVESTIGATOR_815870]  
ï‚· The addition of actual exposure accounting for days where no pi[INVESTIGATOR_60585]  
ï‚· Addition of t he number of subjects with bleeding only epi[INVESTIGATOR_815871]  
ï‚· Change in the definitions of unscheduled and scheduled bleeding and spotting days to use the 
epi[INVESTIGATOR_1841]  
ï‚· Clarification added for imputation for missing bleedin g data to cover scenarios where 3 or more 
days having missing data at the end of the diary data collected  
ï‚· The definition of an evaluable reference period was updated to exclude reference periods where 
there are gaps between the cycles  
ï‚· Cumulative absence of  withdrawal bleeding  rate added as an endpoint  
Statis tical Analysis Plan  
Final  
Effective Date: 11-Dec-2018/Version 3.0 
Sponsor: Estetra  
Protocol no: MIT -Es0001 -C302  
PRS 005 T 17 E  Page 42 of 45 
Strictly Confidential. Â© 2004 -2014, PRA  Health Sciences. All rights reserved.  
ï‚· Bleeding analysis section restructured and split out in to the  classical cycle analysis (including 
early and continued withdrawal bleeding as scheduled) which is now classed as the primary 
definition and the mo dified analysis (including early and continued withdrawal bleeding as 
unscheduled) which is no longer classed as the primary definition  
ï‚· Analyses of bleeding data added for cycles with exactly [ADDRESS_1129825] 2 missed activ e pi[INVESTIGATOR_3353]  
ï‚· The bleeding analysis by [CONTACT_815914]  
ï‚· Clarification on the scales derived for the Menstrual Distress Questionnaire added  
ï‚· Enrolled Population definition correc ted to use the enrollment date  
ï‚· PP Population corrected to make it clear that only the PP Population for bleeding is being derived  
ï‚· Reference to ATC classification removed as data are not coded to ATC in this study  
ï‚· Clarification added to indicate that BMI w ill be programmatically derived from height and weight 
for the vital signs and demography tables  
ï‚· Listing added for the at-risk cycles for each Pearl Index analysis  
ï‚· Clarification added to categorize relationship to study medication as not related and relate d for 
AEs 
ï‚· Change to  the handling of unscheduled laboratory assessments and clarification added for values 
above the upper limit of quantification and values below the lower limit of quantification  
ï‚· Choriogonadotropin beta and eGFR added as laboratory parame ters to be summarized  
ï‚· Addition of summaries and listings of evaluable cycles and reference periods for the bleeding 
analysis  
ï‚· Bleeding and spotting analysis section moved to Section 9.5  
ï‚· Correction to the definition of the alternative definition of at-risk cycles that will be used for the 
derivation of the Pearl Index for method failure pregnancies based on compliance to indicate that 
all 8 criteria need to be met for a cycle to be at-risk 
ï‚· Correction to definition of the presence of a bleeding only unschedu led epi[INVESTIGATOR_815872] a spotting only unscheduled epi[INVESTIGATOR_815873]  
ï‚· Addition of a section for missing or partial dates for AEs  
ï‚· Addition of a new analysis of the method failure Pearl Index i cluding only modified at-risk cycles in 
the denominator where at-risk cycles will be defined as cycles in which no other methods of birth 
control (including condoms and emergency contraception)  are used by [CONTACT_815915] h the dosing rules  3 to 8  in Section 5.1.1  while 
cycles with and without confirmed intercourse are being included in the denominator  
ï‚· Clarification added on how to handle pregnancies for the at-risk cycles when the cycle is not in the 
diary data  
ï‚· Clarification added on the handling of partial dates in the diary data  
ï‚· Addition of summary tables of unscheduled bleeding and spotting days in subjects who had 
unscheduled bleeding and/or spotting epi[INVESTIGATOR_1841]  
ï‚· Clarification added that the exc lusion  of cycles  for unauthorized medications may be different 
between the bleeding analysis and contraceptive efficacy  
ï‚· Clarification added on the inclusion of subjects with an on -treatment or post treatment pregnancy 
but no diary data in the Safety Popula tion and rules were added on how to derive the start and stop 
dates for those subjects  
ï‚· Clarification added that if the subject has an on -treatment pregnancy, then the On -Treatment 
Period for efficacy ends on the estimated date of conception for that subje ct  
ï‚· Addition of summary tables for the number of subjects with a scheduled bleeding epi[INVESTIGATOR_815874]  
ï‚· Clarification added that the day for figures of bleeding by [CONTACT_815916]  
ï‚· WHO drug dictionary version updated  
ï‚· Update to the prior medications definition for contraceptives  
Statis tical Analysis Plan  
Final  
Effective Date: 11-Dec-2018/Version 3.0 
Sponsor: Estetra  
Protocol no: MIT -Es0001 -C302  
PRS 005 T 17 E  Page 43 of 45 
Strictly Confidential. Â© 2004 -2014, PRA  Health Sciences. All rights reserved.  
12.2 Amendment 2 from SAP dated 13 November 2018  
ï‚· Update in the definition for TEAEs to be consistent with the protoc ol and include all AEs starting on 
or after the date of first dose of study medication  
  
Statis tical Analysis Plan  
Final  
Effective Date: 11-Dec-2018/Version 3.0 
Sponsor: Estetra  
Protocol no: MIT -Es0001 -C302  
PRS 005 T 17 E  Page 44 of 45 
Strictly Confidential. Â© 2004 -2014, PRA  Health Sciences. All rights reserved.  
Appendix 1  Glossary of Abbreviations  
Glossary of Abbreviations:  
AE Adverse Event 
ALAT  Alanine Aminotransferase  
ASAT  Aspartate Aminotransferase  
AUC  Area under the c urve 
AUC tau Extent of exposure for the dosing interval  
BLQ  Below the Limit of Quantification  
BMI Body Mass Index  
CI Confidence Interval  
CL Clearance  
Cmax  Maximum concentration  
COC  Combined Oral Contraceptives  
CRF Case Report Form  
CTMS  Clinical Tri als Management System  
DRSP  Drospi[INVESTIGATOR_187306]  
E4/[ADDRESS_1129826]  
max Maximum  
MedDRA  Medical Dictionary for Regulatory Activities  
min Minimum  
n Number of subjects  
NONMEM  Nonlinear mixed effects model  
OFV Objective function  value  
PD Pharmacodynamics  
PK Pharmacokinetics  
PP Per Protocol  
Q1 25th percentile or lower quartile  
Q3 75th percentile or upper quartile  
Statis tical Analysis Plan  
Final  
Effective Date: 11-Dec-2018/Version 3.0 
Sponsor: Estetra  
Protocol no: MIT -Es0001 -C302  
PRS 005 T 17 E  Page 45 of 45 
Strictly Confidential. Â© [ADDRESS_1129827] Error of the Mean  
Tlag  Lag time of absorption  
TEAE  Treatment -Emergent Adverse Event  
TFL Tables, Figures and Listings  
Tmax  Time to maximum concentration  
Vc Central Volume of distribution  
V/F Central volume of distribution  
VPC Visual predictive check  
 